











Title of Document: 
REGULATION OF CALCIUM SIGNALING 
AND CELLULAR LOCALIZATION OF NFAT 
IN CD8+ ANERGIC T CELLS. 
  
 
Mathangi Srinivasan, Doctor of Philosophy, 
2008 
  
Directed By: Kenneth Frauwirth, Assistant Professor, 




Anergy is an important mechanism of maintaining peripheral immune tolerance. T cells 
rendered anergic, are refractory to further stimulation and are characterized by defective 
proliferation and IL-2 production. I have used a model of in vivo anergy induction in 
murine CD8+ T cells to analyze the initial signaling events in anergic T cells. Tolerant T 
cells displayed reduced PLCγ activation and calcium mobilization, indicating a defect in 
calcium signaling. This defect could be overcome by facilitating complete release of 
calcium from the ER. Reduced calcium signaling in CD8+ anergic T cells is therefore 
predominantly regulated by modulations in signaling events upstream of ER store release 
of calcium. Impaired calcium mobilization correlated with a block in nuclear localization 
of NFAT1 in anergic cells, upon stimulation. However, I found that stimulation of 
anergic, but not naïve T cells induced nuclear translocation of NFAT2. This suggested 
 
that NFAT2 is activated preferentially by reduced calcium signaling, and I confirmed this 
hypothesis by stimulating naïve T cells under conditions of calcium limitation (by 
addition of the calcium chelator EGTA), or partial calcineurin inhibition. This 
phenomenon was independent of the phosphorylation activity of the NFAT1 and 2 
kinases p38 and JNK, and resultant nuclear exit, as cellular translocation assays using 
specific kinase and nuclear export inhibitors caused no change in pattern of NFAT1 and 
NFAT2 nuclear localization. Proliferative and transcriptional changes were also observed 
under conditions of calcium limitation or sub optimal calcineurin activity. Thus, my work 
provides new insight into how T cell stimulation conditions might dictate activation of a 
specific member of the NFAT family and aid in differential transcriptional activation. My 
results have also led to the hypothesis that NFAT1 and NFAT2 transcriptional activation 
profiles in anergic T cells are different from responsive T cells. The preferential nuclear 
accumulation of NFAT2 in anergic T cells might be important for the regulation of genes 
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T lymphocytes are key components of the adaptive immune response. This constitutes the 
organism’s antigen specific responses against both intracellular and extracellular 
infective agents, following the first wall of defense-innate immunity. T cells recognize a 
diverse array of antigens targeted to them by specialized antigen presenting cells (APCs). 
These antigens are peptide fragments processed by the APCs and bound to polymorphic 
molecules called the major histocompatibility complex molecules (MHC). Recognition 
and subsequent activation of the antigen specific T cell requires both peptide and MHC 
binding to the T cell receptor complex and other surface molecules. 
1.1 The T cell repertoire 
 
1.1.1 CD4+ T cell subset 
 
Approximately 65% of the mature T cells present in the body are CD4+ helper T cells. 
These cells are considered the master regulators of the immune response, as they control 
B cell and CD8+ T cells responses to their respective antigens (adaptive immunity), as 
well as the macrophage mediated phagocytosis (innate response) (Figure 1.1). CD4+ T 
cells are activated by TCR engagement with MHC class II-peptide complexes. Activated 
T cells aid in the anamnestic or secondary immune response, by promoting B cell class 
switching and affinity maturation and by enhancing cytotoxic responses.  A number of 















































Figure1.1: The CD4+ and CD8+T cell subsets. The T cell repertoire consists of the two 
subsets of cells, CD4+ and CD8+ T cells. A. Antigens from both intracellular and 
extracellular microbes are presented to CD4+ T cells by antigen presenting cells (APCs) 
on MHC class II molecules.  Activated CD4+ T cells perform a number of functions that 
mediate pathogen clearance. CD4+ T cells aid in B cell differentiation and class switching 
by CD40L/CD40 interactions and also by release of cytokines such as IL-4, IL-5 and IL-
13. These cells also mediate maturation of macrophages and enhance their phagocytic 
capability, by release of cytokines such as IFNγ. CD4+ T cells also help in CTL 
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differentiation and resultant cytotoxicity by means of release of IL2, IFNγ and direct 
CD40L/CD40 interactions. Upregulation of MHC and costimulatory molecules on 
activated macrophages also enhances CD8+ responses. B. CD8+ T cells are activated by 
APCs presenting antigens from infected cells (viral and microbial infection, tumors) on 
MHC class I molecules.  Activated CD8+ T cells or cytotoxic T lymphocytes (CTLs) 
mediate direct killing of infected cells by release of molecules such as granzyme B and 
perforin that induce apoptosis of infected cells and by release of IFNγ. Apoptosis of 

















effector functions during a primary CD8+ response[1, 2] and an efficient secondary 
memory recall response [3, 4]. Cytokine production and cell-cell interactions are often 
used ways by which CD4+ T cells communicate with the other immune cells involved in 
the response. The various CD4+ T cell produced cytokines that are employed in immune 
cell activation include IFNγ, IL-2, IL-4, IL-5 and IL-12. CD40/CD40 ligand interactions 
between  T cells and B cells or  T cells [5, 6] are another important activating 
mechanism.  
1.1.2 CD8+ T cell subset 
 
The CD8+ subset is the immune system’s defense against intracellular microbes such as 
Mycobacterium tuberculosis, Listeria monocytogenes, and viruses which invade the cell 
(Figure 1.1).Ppresentation of antigens from these organisms or other intracellular viruses 
is mediated by the proteosomal machinery of the cell. All translation products inside the 
cell undergo a defined amount of proteosomal degradation and the degraded peptides are 
presented by the MHC class I molecules to the T cell population circulating in the 
peripheral lymph nodes. When the cell produces virally encoded proteins, which differ 
from the host cell, or when the antigens from the microbes residing in organelle 
compartments of the cell are presented to the CD8+ T cells, a productive response ensues. 
CD8+ T cells are also essential components of the immune system’s tumor surveillance 
mechanisms. Tumor cells are transformed cells which might express modified versions of 
host proteins. Since the TCR specificity for antigens is defined by a very narrow range of 
residues, any mutations in the amino acid compositions of these self proteins could 
trigger a T cell response. Graft rejection is the CD8+ response to non autologous tissue or 
organ transplants. Since the MHC molecules themselves are highly polymorphic, MHC-I 
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molecules present on the surface of the transplanted tissue could act as foreign antigens 
and cause rejection of the graft. 
1.2 Signal transduction during T cell activation 
 
Antigen-MHC recognition by the T cell leads to a cascade of signal transduction events, 
culminating in the activation of transcription factors, which regulate the expression of 
different proliferative and effector cytokines and proteins [7]. Signal transduction after T 
cell engagement with MHC-peptide presenting APCs or with antibodies can be broadly 
divided into the proximal events that take place immediately after TCR engagement, and 
the distal signaling processes that are activated as a result of these proximal events. 
Signal transduction downstream of T cell receptor stimulation consists of arrays of 
signaling cascades that intersect with each other at various points to generate a complex 
network of events that determine the various functional outcomes of T cell stimulation 
(Figure 1.2).  
1.2.1 Proximal signaling events 
 
When the T cell receptor complex is engaged by the MHC antigen complex, the 
accessory molecules such as the CD4+ or CD8+ molecules, the costimulatory CD28 
molecule, and the T cell surface integrins aggregate around the TCR complex. This forms 
the supra-molecular activation complex (SMAC) or immunological synapse, which has 
been proposed to increase the affinity of the interaction and initiates the biochemical 
events which start the signal transduction cascade. These are defined by a number of 


















































































































































































































































































































































































































































































































































































































































































































































Figure 1.2: Signaling events mediated by T cell stimulation. TCR and CD28 
engagement lead to a network of downstream events that lead to transcriptional activation 
of genes involved in productive immune responses. The MHC-peptide complex interacts 
with the TCR complex and CD4/8 leading to the phosphorylation of the cytoplasmic 
ITAMS of the  chains of the TCR by Lck, associated with CD4/8. ITAM 
phosphorylation recruits ZAP-70 that then undergoes phosphorylation. Phosphorylated 
ZAP-70 mediates the phosphorylation of LAT, which then binds SLP-76. These adaptor 
proteins, lead to recruitment of effector proteins such as Grb2, Vav and PLCγ. Vav 
mediates GTP binding of Rac1 and Cdc 42, which upon further interaction with WASP 
leads to actin cytoskeleton reorganization. Rac1-GTP and Cdc42-GTP also contribute to 
the activation of the MAP kinase pathway. Grb2, upon LAT binding recruits the GEF 
SOS, which activates Ras. Ras-GTP also contributes to the MAP kinase pathway. PLCγ 
is activated by phosphorylation and mediates the conversion of PIP2 to IP3 and 
diacylglycerol (DAG). IP3 generation is the first step in the signaling cascade leading to 
the influx of extracellular calcium (see Figure 3). DAG leads to the activation of PKCθ, 
leading to the recruitment of the Carma1, Bcl-10, MALT1 proteins that further recruit the 
IKK complex. This complex mediates the degradation of IκB, freeing the transcription 
factor NF-κB and leading to nuclear translocation of NF-κB. DAG also activates Ras-
GRP another GEF that leads to the activation of Ras. CD28 engagement results in the 
recruitment and activation of the p85 subunit of PI-3K to the membrane, causing Akt 
actviation. Akt has many downstream functions including regulation of glucose 
metabolism, regulation of cell survival and activation of mTOR. Actviated PI-3K also 
aids in the activation of PKCθ contributing to the activation of NF-κB. CD28 stimulation 
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also leads to Grb2 recruitment. The MAP kinase pathway leads to the formation of the 
transcription factor AP-1. Calcium signaling leads to the nuclear translocation and 
activation of the NFAT family of transcription factors. NFAT, AP-1 and NF-κB are the 
three main transcription factors that are involved in regulation of gene expression 




















tyrosine residues on the ITAMs of the CD3 and ζ chain polypeptides by the Src family 
kinase Lck. Lck is bound to the cytosolic tail of the CD4+ or CD8+ molecules. 
Phosphorylation of the ITAMs recruits ZAP70 to the synapse, that then binds to the 
tyrosines at its SH2 domains [8]. Activation of ZAP70 by phosphorylation results in 
subsequent phosphorylation of its substrates LAT and SLP76. LAT is a transmembrane 
protein important for docking of various signaling proteins to lipid rafts formed in the 
immunological synapse. The LAT and SLP-76 adapter proteins, by their concerted action 
recruit molecules such as Grb2/Gads, Vav, PI-3K and PLCγ to the plasma membrane [9]. 
From this signaling node, the various proteins interacting with LAT and SLP-76, initiate 
signaling events that contribute to the various structural and functional changes that the T 
cell undergoes when activated.  
 
Phosphorylated SLP-76 promotes the phosphorylation of Vav, which leads to Nck 
recruitment. The Vav-Nck complex then enables GTP-bound Rac-1 and Cdc42 to bind 
WASP. WASP then promotes active actin nucleation and cytoskeletal rearrangement. 
This rearrangement aids in the stabilizing of the immunological synapse and strengthens 
adhesion. The SH3 domains of Grb/Gads bind to the Ras guanine nucleotide exchange 
factor (GEF), SOS, which activates the Ras signaling pathway by catalyzing GDP release 
and subsequent GTP binding. Ras-GTP recruits the serine/threonine kinase Raf that 
further leads to the activation of the MEK/ERK MAP kinase signaling pathway [10].  
PLCγ is activated by phosphorylation, leading to the cleavage of Phosphatidyl inositol 
bisphosphate (PIP2) which is an integral plasma membrane lipid. PIP2 is cleaved into the 
second messenger inositol trisphosphate (IP3) and membrane component diacylglycerol 
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(DAG). Signaling events downstream of DAG generation also feed into the MAP kinase 
pathway. 
 
1.2.2 The MAP kinase signaling pathway 
 
DAG is the membrane integral subunit of PIP2 and is the upstream effector involved in 
the activation of NF-κB and AP-1, two  transcription factors, which are necessary for 
complete activation of the T cell [11]. DAG recruits RasGRP1, that functions as a GEF in 
catalyzing GTP binding and activation of Ras, which leads to a step wise kinase cascade. 
MEK1, 2 are the MAP kinase kinases involved in activation of the ERK MAP kinase. 
ERK activation leads to the synthesis of the Fos subunit of the AP-1 heterodimer by 
activation of the transcription factor Elk-1. p38 MAP kinase is also involved in Fos 
generation. This protein is activated by kinase activity of MKK3 and 6, a downstream 
target of the Rac1/Cdc42 pathway that is activated by LAT-Vav interactions. AP-1 is an 
important transcription factor that regulates essential gene expression after T cell 
stimulation. AP-1 is a heterodimer consisting of the c-Fos subunit and the c-Jun subunit. 
The c-Jun subunit of AP-1 is phosphorylated by the JNK MAP kinase. This is activated 
by MKK 4 and 7, targets of the Rac pathway [12]. 
 
DAG is also responsible for the plasma membrane localization of PKCθ. Membrane 
localized PKCθ recruits the Carma1/Bcl10/MALT1 complex that is essential for 
activation of the IKK complex that leads to IκB degradation. In resting cells, NF-κB is 
present cytosolically bound to IκB. This is an inhibitory molecule and prevents nuclear 







calcium (described below) together activate the membrane proximal PKCθ molecules 
which phosphorylate IκB on specific serine residues [13]. Phosphorylation targets IκB for 
ubiquitinylation and proteosomal degradation. This releases the NF-κB which then moves 
into the nucleus and contributes to gene transcription. 
1.2.3 Costimulation during T cell stimulation 
  
During TCR engagement, a number of accessory molecules interact with the APC and 
enhance stimulation. The CD28 T cell surface receptor is bound by the B7.1 and B7.2 
molecules on the APC. This binding clusters the CD28 molecule into the immunological 
synapse formed at the T cell-APC interacting surface. Lck, bound to the cytosolic region 
of CD28, mediates phosphorylation of the tyrosine residues on the cytosolic portion of 
CD28, leading to important downstream signaling events including recruitment of PI-3K 
and the Grb-2 adaptor protein.  The p85 regulatory subunit of PI-3K binds to CD28 while 
the p110 catalytic subunit of PI-3K phosphorylates inositol phospholipids to generate 
PIP2 and PIP3 [14], that induce recruitment of proteins with plekstrin homology (PH) 
domains such as PDK-1. PDK-1 activates the Akt kinase, which is important in 
mediating several functions including the regulation of glucose metabolism, inhibiting 
apoptosis and promoting cell survival by mediating upregulation of anti-apoptotic genes 
such as Bcl-2, and activating mTOR to aid in protein translocation [15]. PDK-1 also 
promotes the plasma membrane localization of PKCθ [16] that mediates NF-κB 
activation as described above [17]. Activation of PI-3K also helps in recruitment of Rac1 
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and Cdc42 by SH3 domain dependent binding [18]. This event brings these proteins to 
the site of their interaction with the guanine nucleotide exchange factor Vav, which is 
recruited by Grb-2 binding, to the cytoplasmic tail of CD28. These events result in the 
conversion of the inactive GDP forms of Rac1 and Cdc42 to the active GTP 
conformation. These interactions further lead to WASP mediated actin cytoskeleton 
reorganization [19]. Signals downstream of these proteins have also been implicated in 
p38 and JNK activation and therefore, might contribute to the organization of the 
transcription factor AP-1. Studies have shown that JNK activity is dependent on CD28 
mediated signaling events [20]. The correlation between CD28 mediated signaling and 
AP-1 activity has also been established by luciferase transcriptional activity assays[21].  
 
Another key interaction downstream of CD28 engagement is the downregulation of 
cAMP accumulation. cAMP is inhibitory for T cells and has been shown to interfere with 
T cell activation and proliferation. CD28 stimulation has been shown to induce 
expression of a cAMP phosphodiesterase PDE7 that decreases levels of cellular cAMP 
[15, 22].  
 
Costimulation is an integral component of T cell activation, as it is required for complete 
activation. The absence of costimulation leads to an impaired T cell response that will be 
described in detail later. Also the presence of inhibitory receptors such as CTLA-4 that 
bind the same ligands (B7.1, B7.2) as CD28 downregulate T cell activation signals and 
inhibit cell proliferation and cytokine production[23]. CD28 deficient mice also display 
defective cytokine production and effector T cell functions [24], underscoring the 
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importance of CD28 mediated signaling in obtaining an optimal T cell response. Thus the 
presence of positive a costimulatory signal is essential for complete T cell activation. 
 
1.2.4 Calcium signaling – Intracellular store release 
 
IP3 that is generated from PLCγ mediated PIP2 cleavage is an important second 
messenger molecule that initiates the intracellular influx of calcium into activated T cells. 
The mobilization of calcium within the cell is a key signaling process which dictates the 
downstream effectors. The calcium response to stimulation in T cells is a biphasic event 
divided into the initial intracellular store release of calcium and the subsequent global 
calcium influx from the plasma membrane channels [25] (Figure 1.3). In T cells, an 
initial peak in cytosolic calcium levels is followed by a sustained high concentration of 
calcium lower than the peak value. This sustained increase in calcium levels is essential 
for the transcriptional regulation which follows [26]. 
 
IP3 is the best characterized second messenger involved in calcium signaling [27]. IP3 
binds to the IP3 receptor on the surface of the ER, which is an important store for 
intracellular calcium [28]. The IP3 receptor is also the channel supporting calcium 
movement on the ER membrane. The interaction between IP3 and its receptor causes 
intracellular store release of calcium into the cytosol. Three subtypes of the receptor have 
been identified. Using knockdown and mutational studies in the Jurkat T cell lines, the 
IP3R1 subtype has been implicated in T cell activation by Jayaraman et al.[29] Upon 





































Figure 1.3: Calcium signaling in T cells. Intracellular mobilization of calcium in T cells 
after activation is a biphasic process, the first being the store release of calcium, leading 
to the second large scale influx of extracellular calcium. (1) Proximal signals downstream 
of TCR engagement lead to the generation of IP3 from PIP2.  IP3 binds to the IP3 receptor 
(IP3R) on the ER membrane, causing release of calcium from the ER stores (2). Two 
other second messengers cADPR and NAADP, have been implicated in release of 
calcium from the intracellular ER stores (2). cADPR binds to the ryanodine receptors on 
the ER membrane resulting in calcium release. The NAADP receptors have not been 
identified yet. The TCR related signals (1) that regulate cADPR and NAADP activity, are 
also not known. STIM1, an ER membrane protein is bound to calcium in the ER, in 
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resting T cells. Second messenger mediated calcium release from the ER leads to the 
aggregation of STIM1 molecules in close apposition to the plasma membrane CRAC 
channels (3). STIM1 migration to the plasma membrane leads to its interaction with Orai-
1, a pore subunit of the CRAC channels, leading to the activation of the channels and 
influx of extracellular calcium (4). Other plasma membrane calcium channels such as the 






















residues [30]. However, the finding that the type I receptor is the predominant receptor 
expressed in T cells has been challenged over the years by other studies that show  
calcium signaling in the absence of the receptor type I [31]. It has been suggested that the 
three receptor subtypes exhibit functional redundancy and the role of the three isoforms 
still needs to be resolved completely in primary T cells [32]. 
 
 There has been increasing evidence of at least two other second messengers implicated 
in calcium signaling [33]. In the Jurkat T cell line, microinjection of cADPR, a cyclic 
derivative of NAD produced by the catalytic action of cADP ribosyl cyclases [34], 
induces calcium flux [35], and addition of an antagonist of this molecule abolishes anti-
CD3 induced free calcium increase in the cytosol [36]. These results suggested that 
cADPR could cause ER calcium release. cADPR binds to the ryanodine receptor, another 
receptor-calcium channel isolated on the ER membranes in T cells [37]. Similar to the IP3 
receptors, the ryanodine receptor is phosphorylated transiently after T cell activation [38].   
 
Another calcium second messenger that has been identified in T cells is NAADP [39]. 
NAADP synthesis is also catalyzed by the cADP ribose-cyclase at acidic pH in the 
presence of nicotinic acid by a base exchange reaction using NADP as a substrate [40]. 
Similar to the cADPR experiments, microinjection of NAADP at nanomolar 
concentrations induced a calcium response in Jurkat T cells as visualized by single cell 
microscopy [41]. The ryanodine receptors have been implicated as potential targets for 
the NAADP ligand [42]. Significantly NAADP is self desensitizing at micromolar 
concentrations.  Experiments where Jurkat T cells were microinjected with these self 
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desensitizing concentrations of NAADP showed abrogation of any calcium signals when 
co-injected with IP3 or cADPR agonists. This shows that NAADP signaling maybe 
required for the activity of the other two second messengers.  
 
ER store depletion is an essential step in the T cell activation cascade, and facilitates the 
second phase of calcium signaling. The large scale influx  of calcium from the plasma 
membrane calcium channels is required for the activation of further downstream effectors 
[43]. Store Operated Calcium channels have been a subject of study for a long time, but 
the molecular identities of many proteins involved in the capacitative calcium entry 
directed by store release have only been identified in the past 2-3 years [44]. As 
determined by the electrophysiological and biophysical properties of the calcium current, 
the predominant calcium current in Jurkat T cells is the ICRAC [45]. The 
electrophysiological properties of the CRAC current have been well established and are 
unique to the channels. CRAC channels display a characteristic I-V relationship with a 
high selectivity of calcium against monovalent ions such as sodium. The current shows 
inward rectification and has a dual specificity for the drug 2-aminoethoxydiphenyl borate 
(2-APB).  
 
There have been a few hypotheses to explain the signal that transpires between the ER 
and the plasma membrane channels. One hypothesis states that the calcium released from 
the ER is essential for activation of the surface channels [46]. This has been disproved by 
a few studies where the presence of cytosolic calcium chelators after thapsigargin 
induced store release of calcium did not inhibit the opening of the plasma membrane 
 
 18 
channels [25, 44]. Thapsigargin also induced calcium influx from the extracellular 
medium in IP3 receptor knockout cells, which proves that the second messenger system is 
just a means of releasing the calcium from the store and is not required for the global 
phase of calcium signaling [32, 47].The most prevalent hypothesis is that the emptying of 
the store calcium provides a signal to the plasma membrane calcium channels, which 
activates them and results in calcium influxing into the cytosol. This signal could be a 
soluble factor which translocates from the ER when the stores are emptied and causes 
SOC channel activation. 
 
 Recently, a number of studies using genome wide RNAi screens in the Drosophila S2 
cells have yielded information about both the ER component that signals store depletion, 
and the molecular subunits of the CRAC channels. From a large scale suppression of 
genes that are involved in thapsigargin mediated calcium release, STIM1 was identified 
as an important gene regulating the SOC current [48]. Further studies identified that 
STIM1 resides in the endoplasmic reticulum in resting T cells and migrates to the plasma 
membrane when store depletion takes place [49]. This study also showed that EF hand 
mutants of STIM1 constitutively activated CRAC channels, providing information about 
the molecular mechanisms that might be involved in STIM 1 mediated SOC activation. 
The conserved calcium binding EF hand motif found in STIM1 is found inside the lumen 
of the ER, where STIM1 monitors the internal calcium concentration of the ER. The EF 
hand mutants constitutively localize to the plasma membrane, suggesting that store 
depletion leads to a downregulation of STIM1-calcium interaction that signals movement 
of STIM1 from the ER into the plasma membrane [50]. Later studies have identified that 
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STIM1 does not necessarily integrate into the plasma membrane. In resting cells, STIM1 
has a diffused ER localization, while store depletion causes STIM1 to move into puncta 
or aggregates on the surface of the ER that is in close apposition with the plasma 
membrane. This localization has been analyzed by electron microscopy and has been 
found to be close enough for direct interactions with the plasma membrane or other 
transmembrane proteins integrated into the PM [51]. The direct correlation between  
STIM1 movement and activation of CRAC channels has been shown by Luik et al. who 
showed that STIM1 clustering near/at the plasma membrane preceded the large influx of 
calcium current [52].  
 
Adopting a similar approach of genome wide RNAi screens, two other studies have 
identified another molecule that is involved in mediating the CRAC current. Vig et al. 
[53] identified two genes, that when suppressed with specific interfering RNA, inhibited 
store operated calcium current. These molecules were termed CRACM1 and CRACM2 
(CRAC modulators), and a secondary patch clamping screen confirmed that these 
proteins were essential for normal CRAC current.  The plasma membrane localization 
and the transmembrane domains present on these proteins also indicated that they either 
formed a part of the actual CRAC channel or regulate CRAC activity directly at the 
plasma membrane level.  
 
Another study performed by Feske et al. [54] arrived at similar results. Using the high 
throughput RNAi screen in Drosophila, in parallel with a positional cloning approach, 
this study also identified the CRACM proteins as involved in the activation of the CRAC 
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channels. The CRACM1 protein was designated Orai1. Previously, this group had studied 
the signaling alterations in human peripheral T cells obtained from two patients suffering 
from severe combined immune deficiency (SCID) and had discovered that these T cells 
displayed grossly impaired intracellular calcium mobilization and resultant NFAT 
translocation and activity [55, 56]. The calcium defect in these cells were identified to be 
after ER release and therefore the mutation in these patients corresponded to a 
protein/proteins involved in the second phase of calcium influx. The mutation was 
tracked to Orai1 by complementation and sequencing the endogenous Orai1. 
 
Further studies have identified that Orai1 and STIM1 interact with each other [57] and 
that the STIM1 puncta formed near the plasma membrane colocalize with Orai1 on the 
plasma membrane [51]. These two proteins have now been shown to traffic to the 
immunological synapse during T cell activation [58], leading to the hypothesis that 
proximal signaling after TCR engagement might be involved in the regulation of the 
CRAC channel assembly and function. Mutational studies have also established that 
Orai1 is the functional pore subunit of the CRAC channel.  
 
There is still a lot of work to be done in characterizing the T cell CRAC channel. 
Although Orai1 and possibly STIM1 form part of the channel, there could be other 
possible channel components that are yet to be identified. Also, although STIM1 
movement into localized puncta and interaction with Orai1 has been identified to activate 
the CRAC channel, there could be other signaling processes that synergize with this 
event. The mechanism by which STIM1 goes from a diffused state to its plasma 
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membrane proximal clustering state after store release is also at present unresolved. The 
contribution of the actin cytoskeleton in establishing the physical interaction between 
STIM1 and Orai1 could be a potential model. WAVE2, a Rac1 effector molecule has 
been shown to be required for actin reorganization and β-integrin mediated adhesion in 
activated T cells [59]. This protein has also been shown to regulate store operated 
calcium influx and could potentially act as a functional scaffold to maintain Orai1 and 
STIM1 interactions and the integrity of the CRAC channel.  
 
Although CRAC channel mediated calcium influx and the discovery of the Orai and 
STIM proteins have taken centre stage in the study of calcium signaling in T cells, there 
have been studies on other type of calcium channels such as voltage gated calcium 
channels and the TRPM channels. T cells have been shown to express both the regulatory 
β4 and pore forming Cav1α1 subunits of the voltage gated calcium channels. The β4 
mutant T cells display impaired cytokine production. IFNγ and IL-4 expression were 
significantly downregulated, while IL-2 expression was moderately decreased [60]. The 
TRPM channels have also been shown to regulate calcium entry into T cells. The TRPM4 
channel gets activated at the peak of a calcium oscillation leading to the depolarization of 
the membrane, reducing the drive for calcium entry. This activates voltage dependent K+ 
currents (Kv1.3) that repolarize the membrane potential, and reestablishes the drive for 
CRAC mediated calcium entry [61]. Thus the various calcium channels that are 
expressed in T cells could play a collective role in maintaining calcium oscillations and 




1.2.5 NFAT signaling 
 
A critical downstream component of calcium signaling in T cells is the activation of the 
NFAT transcription factor family. Calcium, which enters the cell through the plasma 
membrane CRAC channels, binds to the EF hands of calmodulin. This leads to the 
activation of several calcium/calmodulin- dependent proteins including the phosphatase 
calcineurin. Calcineurin is involved in the systematic dephosphorylation of 20-21 serine 
residues on the NFAT proteins that are found in the cytosols of resting T cells. The 
dephosphorylation events mediated by calcineurin uncover the nuclear localization signal 
(NLS) on NFAT, which results in the nuclear translocation of NFAT. Nuclear NFAT 
then undergoes further activation and interacts with a multitude of binding partners such 
as AP-1, T-bet and GATA-3 which result in the coordinate induction of a variety of genes 
that enable productive immune responses and other regulatory mechanisms.  NFAT 
regulates transcription of a wide range of genes, including the positive regulation of 
genes associated with a Th1 response such as IL-2, IFNγ and TNFα, genes such as IL-4 
that are required for a Th2 mediated immune response, and also in negative regulatory 
genes such as Cbl-b and other ubiquitin ligases, which control the strength of activation 
of the T cell. 
 
1.3 The NFAT family 
 
Originally, NFAT was identified as the inducible nuclear factor which bound the antigen 
receptor response element-2 (ARRE-2) of the human IL-2 promoter. Although initially 
considered a single protein, it has now been identified that the NFAT family of 
transcription factors consists of multiple members that are differentially expressed in a 
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multitude of cell types and tissues [62]. Presently, five members of this family have been 
identified and have been termed NFAT1 (NFATp, NFAT-c2), NFAT2 (NFATc, NFAT-
c1), NFAT3 (NFAT-c4), NFAT4 (NFATx, NFAT-c3) and NFAT5 (TonEBP). Of these, 
NFAT5 or TonEBP appears to have special characteristics and is involved in the 
regulation of cellular responses to osmotic stress. The various members of the NFAT 
family have been identified by their sequence similarity in the DNA binding rel-like 
homology domain. Additionally NFAT 1-4 have been defined as the classical members 
of this transcription factor family due to their shared ability to be activated by calcineurin 
mediated dephosphorylation, and to bind to AP-1, an important cooperating transcription 
factor for T cell activation.  
 
These 4 members of the NFAT family have a highly conserved (~65%) Rel homology 
domain, and also comparably bind AP-1 proteins which are necessary for the 
transcriptional regulation of genes involved in immune activation such as IL-2 [63]. 
These proteins have all been shown to bind the distal ARRE-2 site on the IL-2 promoter 
in vitro and therefore all have the capability of regulating IL-2 transcription [62]. NFAT 
binding sites have been found in promoter sequences of a multitude of immune response 
genes such as IL-2, IL-4, GM-CSF, IFNγ, TNF-α and Foxp3  [64], and the number is a 
constantly growing one as more and more genes that are regulated by NFAT activation 
are being discovered. A systematic study to determine the individual family members that 
bind to gene specific promoter leading to transcriptional activation has not yet been 
undertaken. An important consideration when studying NFAT-mediated transcriptional 
activation is the composite interactions with other transcription factors, which enable 
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transcriptional activation or repression. Each of the NFAT family members might possess 
differential specificity for these cooperating proteins, leading to variability in gene 
expression. The similarities and differences of regulation of NFAT cellular localization 
and transcriptional activation, and also NFAT mediated regulation of transcriptional 
activity will be discussed in the relevant sections in this report. 
 
1.4 NFAT mutants 
 
Specific mutations of each of the isoforms of the NFAT proteins have helped to further 
characterize the functional similarities and differences between the different members of 
the NFAT family. Studies using knockout mice for each of the NFAT proteins have 
provided information about the distinct roles that these proteins play in physiology of 
various mammalian cell types during embryonic development. NFAT1 knockout mice 
display aberrant skeletal muscle growth and inhibition of chondrogenesis. NFAT2 
knockout mice have shown defects in heart valve development and abnormalities in the 
cardiac septum. NFAT3 knockout mice are found to have defective formation of primary 
myofibers, that are the first multinucleated muscle cells. NFAT3 and NFAT4 double 
mutants have impaired organization of blood vessels. Thus these proteins play critical 
roles in the organization of different parenchymal tissue during embryonic development 
[65].  
 
NFAT1 and NFAT2 are the two important NFAT family members expressed in 
peripheral T cells. Since these proteins regulate gene expression of an array of genes 
involved in various forms of immune response, knockout studies have yielded 
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information about the functional specificity of these family members and have helped in 
identifying redundant and non-redundant functions for these related proteins. Hodge et 
al.[66] generated NFAT1 knockout mice to look at functional phenotype in T cells. 
Thymocyte development was unimpaired in the knockout mice. NFAT1 knockout T cells 
displayed hyperproliferation and the cytokine profiles of these T cells after TCR 
stimulation was different from wild type cells. IL-4 production at early time points after 
stimulation was decreased in the mutant cells, while IL-2 expression remained unaltered. 
Paradoxically, IL-4 expression and Th2 development was increased at later time points, 
implying that initial early expression of IL-4 might be maintained by NFAT1, but other 
factors independently regulate IL-4 expression during sustained T cell activation. 
Unaltered IL-2 expression could probably be explained by the presence of other factors 
involved in transcriptional regulation of IL-2. Hyperproliferation of T cells in the absence 
of NFAT1 might mean that NFAT1 is important for the expression of genes which inhibit 
T cell activation.  
 
NFAT2 knockouts are embryonically lethal and die by embryonic day 14.5 due to 
congestive heart failure. Therefore, mice with homozygous NFAT2 knockout cells were 
generated using a blastocyst complementation technique with NFAT2-/- embryonic stem 
cells [67]. NFAT2 knockout T cells displayed impaired proliferation, but that did not 
correlate to a decreased production of IL-2. IL-2 levels produced by mutant cells were 
comparable to wildtype cells; therefore the proliferative defect appeared to be an intrinsic 
property of the absence of NFAT2. During an ongoing immune response, the absence of 
NFAT2 resulted in decreased production of Th2 cytokines such as IL-4 and IL-6, but 
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there was no difference in the expression levels of Th1 cytokines such as IFNγ and 
TNFα. Thus NFAT2 appears to be important for the establishment of a Th2 mediated 
immune reponse, and did not seem to have much of an effect on the expression of IL-2 or 
the other Th1 cytokines [67]. 
 
Peng et al. also investigated T lymphocytic properties which were doubly deficient in 
NFAT1 and NFAT2 [68]. Double knockout T cells were generated by fetal liver 
chimerazation in irradiated RAG-2 deficient mice. The proliferative ability of the T cells 
was not markedly diminished, and these cells appeared to be spontaneously activated as 
seen by upregulation of activation markers. The double knockout T cells were severely 
impaired in the production of both Th1 and Th2 cytokines, reiterating the single knock 
out studies that NFAT1 and NFAT2 play important roles in determining the effector 
phenotype of the T cells [68].  
 
These knockout studies have provided valuable information regarding the regulation of T 
cell phenotype after activation and the involvement of the NFAT proteins in the 
maintenance of T cell activation and immune response. NFAT1 therefore, appears to be 
the relevant transcription factor for the production of a Th1 mediated response, while 
NFAT2 skews the response toward a Th2 bias. Spontaneous activation of T cells in the 
absence of these factors implies that NFAT proteins are not only involved in the 
establishment of T cell functions, but also in the inhibition of T cell activity. Also, these 
studies reveal that these proteins have significant non-redundant functions and are 
important in establishing a balance in the manifestation of effector functions of T cells. 
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1.5 NFAT – domain structure 
 
The classical members of NFAT (NFAT1-4) are all made up of three functional domains, 
the Rel-similarity domain (RSD), which is important for DNA binding activity and also 
for cooperative binding with other transcription factors, the regulatory domain or the 
NFAT homology region (NHR), and the transactivation domain (TAD) [62] (Figure 1.4).  
 
The Rel Similarity domain has been named so due to its distant sequence similarity 
(~20%) with the Rel DNA binding domains of NF-κB proteins. This domain is highly 
conserved (60-70%) between the various members of the NFAT family conferring some 
amount of overlap of DNA binding and gene regulation. NFAT binds with DNA in the 
major groove of the 5’ half site of the conserved NFAT recognition sequence 
5’GGAAAA 3’. The protein has another DNA binding site of about 20 amino acids 
referred to as the Rel-insert region (RIR) which contacts the 3’ half site at the minor 
groove. These two interactions stabilize the DNA-NFAT contact and enable NFAT to 
bind promoter DNA as monomers, which NF-κB is unable to do. The NFAT consensus 
recognition sequence is conserved in all the conventional members of the NFAT family, 
which explains the ability of all these proteins to bind the ARRE-2 site of the IL-2 
promoter, at least in vitro. This domain is also required for the binding of NFAT to other 
transcription factor partners such as AP-1. The cooperative binding between these two 
proteins synergistically increases the affinity of the individual proteins for the DNA. AP-
1 interacts with NFAT through hydrogen bonding and electrostatic interactions that 
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Figure 1.4: Domain Structure of NFAT proteins. NFAT proteins have three 
functionally important domains, the N terminal transactivation domain (TAD), the 
regulatory domain or the NFAT homology region (NHR) and the DNA binding domain 
or the Rel similarity domain (RSD). Specific serine residues in the N terminal TAD 
undergo phosphorylation reactions that are required for NFAT activation. The RSD is 
involved in binding to promoter/enhancer sequences of genes that are regulated by 
NFAT. Protein-protein interactions with other transcription factors such as AP-1 also take 
place in the DNA binding domain. The regulatory domain has calcineurin docking sites, 
and also has the serine residues that are dephosphorylated by calcineurin to result in 
nuclear translocation. Calcineurin binding site A (PxIxIT) is highly conserved among all 
the members of the NFAT family and is found toward the N terminal end of the domain. 
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The second calcineurin docking site is found only in NFAT2 and NFAT4 proteins. The 
regulatory domain also consists of serine rich sections that are termed SRR1 and SRR2 
and three serine-proline repeat motifs (SPxx motifs). Calcineurin mediates 
dephosphorylation of 18-21 serine residues across these sections. The NLS or the nuclear 
localization sequence is also present in the regulatory domain. In the conformation of 
NFAT found in resting cells, the NLS is masked, but calcineurin mediated 



















The NFAT homology domain or the regulatory domain is about 320 amino acids long 
and is found toward the amino terminal end of the NFAT protein. This domain consists of 
regions that have a number of serine residues that are dephosphorylated by calcineurin. 
This domain also contains the calcineurin docking site (PxIxIT) which is highly 
conserved between all the NFAT family members. All the variable residues in the PxIxIT 
motif are made up of polar residues. In NFAT1 and NFAT2, the sequence is SPRIEIT, 
and in NFAT3, this sequence is CPSIQIT, and in NFAT4 it is CPSIRIT. Mutation of 
these polar residues to alanine decreased calcineurin-NFAT binding, which underscores 
the importance of this particular motif sequence for calcineurin- NFAT interactions [69]. 
This site is called Calcinurin binding site A and is present in all the members.  
 
In NFAT2 and 4, the C terminal region of the NFAT homology domain contains another 
binding site called calcineurin binding site B [70]. This region is distinct from the 
conserved PxIxIT arrangement and has been found to be necessary for calcineurin 
interaction with NFAT2 and 4 in vivo. The peptide stretch corresponding to the second 
calcineurin binding region in NFAT1 did not mediate calcineurin binding in vitro. This 
provides evidence for an important regulatory event that is unique to NFAT2 and not 
NFAT1 that might prove important in defining the cellular and functional roles that these 
proteins play. 
 
The regulatory region controls the cellular localization patterns of the NFAT protein by 
the conserved nuclear localization sequence (NLS) present in the domain. The domain 
can be broken down into different conserved motifs which are rich in serine residues; the 
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SRR1 (serine rich region) 170SPASSGSSASFISD183 and three serine proline repeat motifs 
[SPxx]SPxxSPxxSPxxxxx[D/E][D/E] [71]. The SRR motif is required for the 
maintenance of the NFAT proteins in the cytosol of resting cells, and deletion of this 
motif results in constitutively nuclear localization [72]. The NLS sequence is masked 
when the SRR1 motif is completely phosphorylated, and is uncovered upon calcineurin 
mediated dephosphorylation of serine residues in the SRR1 peptide region. The 
unmasking of  the NLS then leads to translocation of the NFAT proteins into the nucleus 
via the cell’s importin machinery [73]. 
 
The third important functional domain is the transcriptional activation domain. There are 
two transactivation domains in NFAT, one at the amino terminal end of the protein and 
the other at the carboxy terminal end. The N-terminal transactivation domain has been 
described as being more important in determining gene regulation. This domain is highly 
acidic, which is a hallmark of transactivation domains, and renders itself highly amenable 
to phosphorylation. This domain has a number of serine and theronine residues that are 
phosphorylated by a host of proteins leading to transcriptional activation 
 
1.6 Calcineurin mediated dephosphorylation of NFAT 
 
NFAT signaling in T cells is initiated by the dephosphorylation events mediated by the 
Ca+2 /CaM-dependent serine/theronine phosphatase calcineurin [74]. Calcineurin consists 
if two functional domains, the catalytic calcineurin A (CnA) and the regulatory 
calcineurin B (CnB).  The catalytic domain binds to the conserved calcineurin binding 
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site on NFAT proteins [75]. The calcium/calmodulin complex activates calcineurin by the 
displacement of an autoregulatory peptide that is found near its catalytic site [62].  The 
individual members of NFAT bind calcineurin with low affinity (Kd= 10-30µM-1) needed 
to maintain sensitivity to activation signals and prevent constitutive binding and resultant 
deposphorylation [69]. 
 
Calcineurin activity is downregulated by a host of cellular and pharmacological inhibitors 
which therefore interfere with NFAT dephosphorylation. The AKAP79 scaffold protein 
binds to calcineurin and prevents access to substrates such as NFAT [76]. Cain/Cabin 1 
directly binds to calcineurin and inhibits enzymatic activity [77].  The calcineurin B 
homolog CHB binds calcineurin A but is unable to induce phosphatase activity. The 
MCIP1, 2 and 3 proteins, also termed DSCR proteins, are also able to block calcineurin 
activity. Thus, there are a number of negative regulatory proteins that can inhibit 
calcineurin mediated NFAT dephosphorylation, and that could therefore contribute to the 
overall regulation of cellular localization and activation of NFAT. The pharmacological 
inhibitors cyclosporin A (CSA) and FK506 are also widely used to downregulate 
calcineurin activity. These molecules are used as immunesuppressive agents as they 
potently inhibit calcineurin mediated dephosphorylation and NFAT transcriptional 
activity. CSA and FK506 are microbial products that bind to the intracellular proteins 
cyclophilin and FKBP respectively. These drug-protein composite surfaces bind the 
CnA-CnB complex, preventing substrate access. Various viral and bacterial proteins also 
downregulate calcineurin activity and prevent immune responses through NFAT 
transcriptional activation as an immune evasive strategy. Notably, the A238L protein of 
 
 33 
the African swine fever virus binds the calcineurin complex much like CSA to prevent 
activity. Calcineurin is also targeted by pathogens like Trichoderma, Streptomyces and 
leukemia viruses, underscoring the importance of calcineurin activity and consequent 
NFAT activation in promoting productive immune responses [78]. 
 
1.7 NFAT mediated transcriptional regulation 
 
The importance of the NFAT family of transcription factors can be explained by the vast 
array of immunologically relevant genes that are regulated by these proteins. An 
important consideration in studying transcriptional regulation by NFAT is the cooperative 
interactions between NFAT and other transcription factor proteins that are necessary to 
mediate gene expression. NFAT/AP-1 interactions have been studied extensively and 
have been a major focus due to their concerted action in the expression of important 
cytokine genes that define immune responses. NFAT/AP-1 composite sequences are 
present on the promoter/enhancer sites of these genes, and the cooperation between 
NFAT and AP-1 is required to stabilize DNA-protein complex and initiate transcription. 
AP-1 is composed of c-Fos and c-Jun heterodimers, Jun homodimers can also act as 
NFAT binding partners. The amino terminal region of the Rel homology domain of 
NFAT interacts with the leucine zipper regions of Fos and Jun to achieve cooperative 
association on the promoter DNA site [63].   
 
Macian et al. [79] used an NFAT1 mutant protein that could not cooperate with AP-1 to 
identify genes that are dependent on NFAT/AP-1 cooperativity. IL-2 has four to five 
NFAT binding sites, and three of these are composite NFAT/AP-1 binding regions [80]. 
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The distal NFAT site on the IL-2 promoter at -280 bp from the transcription start site 
(TSS) is an NFAT and AP-1 composite site, as is the proximal sequence at -135 bp [81]. 
GM-CSF is another gene with three NFAT/AP-1 cooperative sites. IL-3 is another gene 
that is regulated by NFAT and AP-1, although there exists an upstream enhancer site that 
contains NFAT/Oct binding elements. The requirement of other cooperative factors along 
with NFAT/AP-1 binding is a recurrent theme for genes such as IL-4, IL-5 and IFNγ. IL-
4 has five NFAT binding sites, with three of them being NFAT/AP-1 composite sites, 
while NFAT/GATA3 binding sites are also found on the distal enhancer of IL-4. 
Cooperation between NFAT and other proteins such as c-Maf and NIP45 has also been 
reported. IFNγ, an important Th1 cytokine, has NFAT/AP-1 cooperative site and also has 
sites for cooperation between NFAT and T-Bet. Other genes that have been shown to 
contain NFAT/AP1 sites are FasL, MIP1α, CD25 and Cox2, genes induced during T cell 
activation. In contrast, Macian et al, found that the expression of TNFα appears to be 
independent of NFAT/AP-1 cooperation [79]. The NFAT recognition sequence found on 
the TNFα promoter might accommodate NFAT dimers, or other NFAT binding partners 
might dictate expression. Interestingly, NFAT2 expression in T cells has been shown to 
be regulated by NFAT1 activity [82]. Based on this report, NFAT2 has been termed the 
inducible member of the NFAT family. It is not known if NFAT2 promoter sequences 
have AP-1 composite binding sites in them.  
 
Among the genes that are upregulated independently of AP-1 are genes that are required 
for the regulation of the anergic phenotype. Macian et al.[83] studied the gene expression 
patterns in cells that were treated with ionomycin, which  induces a large influx of 
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calcium and promotes calcium mediated downstream events, without inducing other 
signaling pathways activated by TCR and CD28 stimulation. NFAT nuclear translocation 
and activation in these cells resulted in the upregulation of genes such as Cbl-b, GRAIL 
and DGKα, which program the cells for future anergy or non-responsiveness.  
 
Other significant NFAT cooperative factors such as Smad3 [84], and Foxp3 [85], 
implicate NFAT  in the establishment of the T regulatory phenotype. Tone et al. [86] 
have identified NFAT and Smad3 binding sites in the enhancer regions of the Foxp3 
gene. NFAT and Smad3 binding to these sites appears to promote histone acetylation in 
the enhancer region and positively regulate gene expression. Foxp3 binds regions in the 
regulatory domain of NFAT, at some regions that overlap with AP-1 cooperation. Foxp3 
has also been found to bind AP-1 consensus sequences on the ARRE-2 site of the IL-2 
promoter, and therefore appears to repress IL-2 production by forming cooperative 
complexes with NFAT and DNA, in active competition with NFAT/AP-1/DNA 
complexes. NFAT/Foxp3 cooperativity has been shown to positively regulate expression 
of CTLA-4 and CD25, proteins that are highly expressed by regulatory T cells [85].  
Similar to Foxp3, the inducible cAMP early repressor (ICER) protein acts as a negative 
regulator of transcription of cytokines such as IL-2, IL-4 and GM-CSF. ICER/ NFAT 
complexes have been shown to bind NFAT/AP-1 composite sites on the promoters of 
these genes in human thymocytes [87].  p21SNFT is a leucine zipper protein that binds 
NFAT and Jun, and represses IL-2 production by competing with Fos and preventing the 




The above examples provide an expanding number of genes that are regulated, either 
positively or negatively, by NFAT, based on its cooperating partner protein. Expression 
of genes such as IL-2 appears to be both induced and repressed by NFAT binding to 
promoter DNA, depending on the context of activation and the corresponding binding 
partner. The various signaling interplays that result from T cell engagement under 
different contexts are relayed to the NFAT proteins that, by their specific binding 
interactions dictate the phenotype of the responding T cells  during a productive immune 
response as well as during a tolerant response [89].  
 
1.8 T cell tolerance 
 
The T cell receptor (TCR) is the product of somatic recombination of the V and the J 
germline gene segments in the alpha subunit and the V, D and J regions in the beta 
subunit. The enormous diversity of the TCRs is the result of the random combinations of 
these gene segments, where each combination leads to particular antigen specificity. VDJ 
recombination takes place in the thymus during development, and at this point the 
population consists of thymocytes specific for both foreign as well as self peptides. The 
TCR does not have the innate ability to distinguish between harmless self antigens and 
potentially inflammatory foreign ones. This reactivity and specificity is regulated by a 
series of processes together called tolerance. T cell tolerance is the failure to mount a 
response against an antigenic stimulus. Tolerance can be elicited by a number of 
mechanisms, the main aim of which is to prevent T cells from reacting to self antigens 
and causing unwarranted immunopathology.  The T cell repertoire is subjected to 




Central tolerance is the selection process that takes place in the thymus after the antigen 
receptor has been expressed on the surface of the thymocyte. Self proteins are circulated 
through the thymic blood flow or expressed by cells in the thymus and these are 
presented to the lymphocytes by the resident APCs. When there is a high affinity 
interaction between the TCR and MHC/antigen complexes, these antigen specific T cells 
undergo clonal deletion, as they correspond to self reactive T cells. This is called negative 
selection. 
 
Though negative selection should theoretically delete all the self reactive T cells, there is 
still a percentage of mature peripheral T cells which are either autoreactive or are specific 
to harmless environmental antigens, such as food antigens.  T cell responses mounted 
against these could lead to potential autoimmune disorders or unwarranted 
immunepathology. Peripheral tolerance mechanisms make sure these T cells are 
eliminated, or functionally inactivated. 
 
The establishment of tolerance toward tissue antigens is particularly important for CD8+ 
T cells, due to the presence of MHC class I molecules on all nucleated cells. Even with 
efficient negative selection and removal of self-reactive T cells from the immunological 
pool, there is a necessity for mechanisms of peripheral tolerance to take place. Along 
with potentially pathogenic antigens, the immune system is being constantly exposed to a 
plethora of innocuous foreign proteins, such as food or other environmental antigens. 
These can be cross-presented on MHC class I by dendritic cells (DC) and macrophages, 
and might lead to unwanted immune responses. Peripheral tolerance of naïve CD8+ T 
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cells prevents uncontrolled immune responses toward these antigens. Furthermore, some 
self-antigens might not be expressed in the thymus at levels required for efficient 
negative selection, or have sub-optimal avidity towards antigen-specific T cell receptors 
(TCRs). If these conditions fall under the threshold required for deletion through negative 
selection, then the T cells mature and form part of the peripheral population [90].  
 
Peripheral tolerance can be achieved by multiple means and can be classified into three 
main categories: clonal ignorance, death by deletion, and functional unresponsiveness. 
Low avidity self-antigens, which fail to initiate negative selection, are the most likely 
candidates for clonal ignorance. The TCR/MHC-Ag affinity requirement for normal 
peripheral T cell activation is higher than what results in thymic deletion [91]. Low 
avidity antigens, therefore, might never induce peripheral immune activation, and the 
population of Ag-specific naïve T cells could potentially remain untouched. Peripheral 
ignorance can also be achieved when the antigens are restricted to immune privileged 
sites, such as  across the blood-brain barrier or across the fetal-maternal barrier [91].  
However, this form of tolerance is not permanent, as there are situations where the 
antigen could be presented in the right kind of stimulatory conditions and might cause 
unwarranted immune responses. Alternatively, in conditions where there is uncontrolled 
expression of these self-antigens in concentrations much higher than normal, such as in 
tumor cells, the clonally ignorant T cells might become autoreactive.  
 




An important mechanism of peripheral tolerance in naïve T cells is the induction of 
anergy. Anergy is a form of functional unresponsiveness, believed to occur when a T cell 
has been subjected to MHC-Ag interaction in the absence of costimulation. An anergic T 
cell is rendered refractory to further stimulation, even in the presence of full 
costimulation [92]. Using this definition, many studies have been undertaken to elucidate 
the functional requirements for inducing anergy, and also the biochemical changes that 
are seen in anergic T cells. The hallmarks of anergic cells are defects in proliferation and 
IL-2 production, but other effector functions show variable (or sometimes no) reduction. 
Various models, both in vitro and in vivo, have been used to induce anergy in T cells. 
TCR engagement, either by agonist peptides in the absence of costimulation, or with 
partial agonist peptides in the presence of costimulation, was one of the first methods that 
was used to anergize T cells [93]. Anergy in T cells can also be achieved by stimulation 
with plate bound anti-CD3 antibodies [94] or by treating T cells with the calcium 
ionophore ionomycin [83]. The blockade of costimulation using CTLA-4 Ig during T cell 
stimulation using agonist peptides and splenic APCs is another common approach [95]. 
In vivo, T cells have been anergized by the administration of superantigens, which 
tolerize a portion of the Vβ T cell pool [96]. Administration of single or multiple doses of 
TCR-specific peptides to TCR Tg mice, or adoptively transferring these Tg T cells into 
mice that express the agonist peptide as self-antigen, are other favored techniques that 
results T cell hyporesponsiveness.  Though the above models of induction of anergy all 
result in the corresponding T cells becoming refractory to further antigenic stimulation, 
the cellular mechanisms of anergy induction and the manifestation of the anergic 
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phenotype differ in the various models, prompting a more comprehensive study of the 
models of anergy to define the functional state of non-responsiveness.  
 
Inhibition of cell cycle progression has been studied as a potential contributor to the 
induction of anergy. It has been shown that T cells from mice that lack p27KIP1, a cell 
cycle progression inhibitor, are resistant to anergy [97]. p27KIP1 regulates tolerance by 
preventing the phosphorylation of Smad3, leading to the upregulation of the Cdk 
inhibitor p15, that results in blockade of cell cycle progression [98]. In contrast, A.E7 T 
cells that have been stimulated with anti-CD3 and anti-CD28 in the presence of 
sanglifehrin A, a cell cycle progression inhibitor, promoted cell cycle arrest, but did not 
program the T cells to become refractory to further stimulation [99]. Further studies with 
this model have identified that rapamycin, an inhibitor of mTOR, causes anergy in both 
A.E7 and primary mouse T cells when stimulated in the presence of both signal 1 (TCR 
engagement) and signal 2 (costimulation).  mTOR integrates metabolic environmental 
cues, such as glucose and amino acid availability to dictate cell growth and proliferation. 
Therefore, the discovery that inhibition of mTOR by rapamycin can lead to anergy is 
interesting as it alludes to mTOR function as an integrator of costimulatory cues to direct 
T cells toward anergy or productive activation. Thus, cell cycle arrest might be a 
consequence rather than a cause of T cell anergy [100].  
 
Anergy induction has been studied in great depth using a multitude of experimental 
methods of induction. Though these methods are all experimentally different from each 
other, an integrative paradigm for T cell hyporesponsiveness involves incomplete T cell 
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activation. Stimulation of the TCR (signal 1) in the absence of costimulation (signal 2), 
leads to a refractory state in T cells, and a blockade of cytokine expression (Figure 1.5). 
Initially, CD28 interaction with the B7 molecules on APCs was primarily considered as 
costimulation, but recent studies have spotlighted a number of both positive and 
inhibitory receptors that contribute to costimulation. Importantly, inhibitory molecules 
such as PD-1 and CTLA-4 have been shown to inhibit productive activation. The recent 
report by Zheng et al. [100] implicates mTOR as an integrator of costimulatory cues, both 
positive and negative, to determine the phenotype of the stimulated cell. Thus, if the 
signals from negative costimulatory molecules are more abundant than positive signals 
downstream of the surface receptors, then the cell may be programmed toward anergy. 
 
 The in vivo models represent the physiological conditions that potentially cause anergy. 
Therefore, they contribute toward better understanding of the intracellular and 
intercellular stimuli that can be manipulated therapeutically in using T cell anergy in 
treatment. One such area where mechanisms of T cell anergy or hyporesponsiveness 
could be used in treatment is in immunesuppresive regimens during allotransplantation. 
Cyclosporin and rapamycin are clinically used immune suppressive drugs. In vivo mouse 
models of T cell anergy, that use these drugs, or study molecules associated with these 
drugs, aid in better understanding of the molecular mechanisms that are targeted during 
































Figure 1.5: Two signal model of anergy induction. Productive activation of T cells 
required two signals. Signal 1 consist of MHC-peptide interactions with the TCR leading 
to downstream signaling events, while signal 2 refers to costimulation mediated by CD28 
interactions with CD80/86 molecules on the surface of the antigen presenting cell (APC). 
T cell stimulation in the presence of signal 1 alone induces anergy or functional 






1.8.2 Transcriptional activation during anergy induction 
 
The conclusion that anergy is a programmed state of T cell differentiation, rather than 
just a blockade of a traditional productive immune response, is strengthened by results 
from a number of gene array studies that have determined the transcriptional pattern of 
genes during anergy induction in  comparison with naïve and activated T cells [83, 101, 
102]. A CD4+ in vivo anergy model, of TCR Tg T cells transferred into mice expressing 
the specific antigen constitutively, was used to study the gene expression patterns of 
anergic cells in comparison with naïve T cells and activated T cells [102]. 1176 candidate 
genes from gene array analysis of naïve, anergic and activated T cells, were considered 
and a distinct transcriptional pattern was identified for the anergic T cells. Among the 
genes that were differentially regulated were costimulatory molecules, proteins involved 
in signal transduction, and proteins involved in cell cycle progression. Notably, inhibitory 
surface receptors, such as PD-1 and CTLA-4, showed higher expression in anergic T 
cells than their naïve counterparts. Fyn, a protein kinase involved in proximal signaling 
after TCR engagement, that has been shown to be upregulated in certain models of 
anergy, shows upregulated expression as well. The expression of the cell cycle inhibitor 
p27KIP1 is also significantly upregulated in anergic T cells, providing support for the 
argument that cell cycle arrest is an important contributor to the anergic phenotype.  
 
Macian et al. [83] studied the gene expression patterns of  CD4+ T cells that were 
anergized by ionomycin treatment and found significant differences in the transcriptional 
patterns of these cells in comparison with cells that were activated with PMA+ 
ionomycin (complete signal). Using Affymetrix gene arrays, they have identified genes 
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such as Ikaros, DAGKα, CD98, FasL, 4-IBB-L as being upregulated in anergic T cells. 
Some of these molecules have been further studied to determine their role in anergy 
maintenance and definitive roles have emerged to explain the signaling alterations that 
have been seen in anergic T cells.  
 
An important family of proteins that have been identified by these genetic screens of 
anergic cells is the E3 ubiquitin ligase family [103]. The upregulation of expression of 
ubiquitin ligases such as Cbl-B, GRAIL and Itch in anergic T cells has prompted the 
study of their role in the maintenance of the hyporesponsive phenotype. E3 ubiquitin 
ligases catalyze the transfer of ubiquitin to proteins that are then targeted by the 
proteosomal machinery to be degraded. Thus the E3 ligases might abrogate signaling 
pathways by targeting specific proteins for proteosomal degradation. Monoubiquitination 
mediated by the E3 ligases also serves another molecular purpose. Attachment of a single 
ubiquitin molecule to proteins alters the cellular trafficking patterns of proteins, with the 
ubiquitinated protein targeted to lysosomes. Thus the E3 ubiquitin ligase enzymes might 
negatively regulate signaling machinery by interfering with cellular localization of 
specific proteins [104].  
 
GRAIL (gene related to anergy in lymphocytes) is one such E3 ubiquitin ligase that is 
upregulated in  anergic T cells [105], and the forced expression of GRAIL in naïve T 
cells has been shown to induce anergy in these cells [106]. The molecular targets of 
GRAIL in anergic T cells have not been identified yet, but it has been seen that GRAIL 
colocalizes with the transferrin receptor in anergic T cells and that intact endocytic 
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trafficking is required for GRAIL mediated negative regulation of IL-2 expression [105]. 
Heissmeyer et al. [107] have shown that Cbl-b, Itch, and Nedd4 expression is upregulated 
in  T cells anergized with ionomycin. These proteins were shown to bind to both PLCγ 
and PKCθ to target them for ubiquitination and subsequent degradation. This leads to the 
breakdown of the calcium signaling cascade and the PKCθ dependent MAP kinase 
pathway and NF-κB activation, leading to hyporesponsiveness. Using Cbl-b knockout 
mice, Jeon et al. [108] have confirmed the role of Cbl-b in mediating the degradation of 
PLCγ in in vitro anergized T cells. T cells from the knockout mice were also resistant to 
in vivo induced anergy, both in a peptide injection and in a SEB administration model, 
although PLCγ degradation was not measured in the in vivo models.  
 
Yet another gene chip analysis of anergic A.E7  T cells has identified the upregulation of 
expression of the transcription factors Egr-2 and Egr-3 [109]. Overexpression of these 
proteins resulted in upregulation of Cbl-b and conversely, Cbl-b levels were detectably 
lower in Egr knock out T cells. These transcription factors might therefore act in the 
positive regulation of expression of anergy related genes such as Cbl-b and therefore 
direct the anergic phenotype. 
 
The Gajewski group has performed similar gene expression studies on anergic T cells and 
has identified that DGKα (diacyl glycerol kinase α) expression is upregulated in anergic 
CD8+ T cells [110], similar to the Macian study. DGKα phosphorylates DAG, generating 
phosphatidic acid and reducing the availability of DAG for further downstream signaling. 
Transduction of naïve T cells with adenovirus expressing DGKα caused the cells to 
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display an anergic phenotype. These cells produced decreased amounts of IL-2 in 
response to restimulation. DGKα expression also resulted in diminished recruitment of 
RasGRP1 to the plasma membrane. RasGRP1 has been identified as an important Ras 
guanine nucleotide exchange factor (GEF) that activates Ras signaling in activated T 
cells. The diminished membrane localization correlates with impaired Ras signaling that 
has been seen in anergic T cells. Conversely, reversal of anergy was seen in anergic T  
cells treated with a pharmacological inhibitor of DGKα. The causal role of DGKα in 
regulating the anergic phenotype was corroborated in a study using DGKα knockout mice 
in CD4+ anergy models [111]. DGKα deficient cells were resistant to anergy induction 
both in vitro and in vivo. Thus, inactivation of the Ras/MAPK pathway by DGKα 
appears to be an inhibitory mechanism used for anergy in both CD4+ and CD8+ T cells. 
 
1.8.3 The role of NFAT in anergy induction 
 
The requirement of signal 1, or TCR engagement, for the establishment of anergy 
suggests that signaling events downstream of TCR stimulation might be necessary for the 
expression of the anergy genes. Indeed, calcium signaling and NFAT activation has been 
shown to be indispensable for the upregulation of these genes. Using an ionomycin 
induced anergy model, Macian et al.[83] established the role of NFAT1 in the regulation 
of T cell anergy (Figure 1.6). The upregulation of the anergy related genes was abrogated 
in the presence of cyclosporin A, which inhibits calcineurin activity. In correlation with 
the in vitro data, NFAT1 knock out T cells were resistant to anergy induction and did not 

































































Figure 1.6: Transcriptional activation during anergy induction. T cell stimulation in 
the presence of signal 1 (TCR engagement) with no signal 2(costimulation) leads to 
anergy induction. Signals downstream of TCR ligation result in the nuclear translocation 
and activation of the transcription factor NFAT1. NFAT1 binds to promoter/enhancer 
sequences of genes such as Egr2, Egr3, GRAIL, Cbl-b, Itch and DGK-α and upregulates 
transcription. When anergic T cells are subjected to complete stimulation (signal1+2), the 
E3 ligases Cbl-b and Itch mediate ubiquitination of substrates such as PLCγ and PKCθ. 
Polyubiquitination of proteins leads to subsequent proteosomal degradation, while 
monoubiquitination leads to alteration in cellular trafficking patterns of the proteins. 
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PLCγ and PKCθ have important functions during T cell activation leading to NFAT and 
NF-κB mediated transcriptional activation. DGK-α is a kinase that phosphorylates 
diacylglycerol to form phosphatidic acid. This depletion in DAG concentrations in T cells 
leads to impaired Ras signaling and MAP kinase activation, as well as reduced NF-κB 
activation. MAP kinase activity is required for the formation of the transcription factor 
AP-1. Thus the proteins, whose expression is upregulated during anergy induction, lead 
to the attenuation of T cell activation signals during restimulation, yielding a net result of 


















transcription factor associated with promoting a productive immune response being 
necessary to induce a hyporesponsive phenotype was solved by the discovery that AP-1 
cooperation is absent in T cells stimulated under anergizing conditions. Macian et al. 
demonstrated this elegantly, using an engineered NFAT1 derivative incapable of 
associating with AP-1. Cyclosporin treatment also abrogated the proteosomal degradation 
of PLCγ and PKCθ that were seen in anergic T cells [107].  
 
Thus, NFAT1 appears to play a pivotal role in both transcriptional regulation of genes 
involved in a productive immune response and in establishing T cell non-responsiveness. 
This dual and antagonistic functionality of NFAT is achieved by differential association 
with binding partners. Thus AP-1 is indispensable for expression of genes such as IL-2, 
IFNγ, IL-4 and granzyme, while transcriptional activity of genes such as Cbl-b, Egr2, 
Egr3 and DGKα require only NFAT binding to promoter/enhancer sequences. Although, 
experimental evidence has been acquired only for NFAT1 requirement in anergy 
induction, other members of the NFAT family such as NFAT2 and NFAT 4, might also 
be involved. Also, NFAT could potentially cooperate with transcriptional partners other 









2. Methods and Materials 
 
2.1 Antibodies and reagents 
 
Anti-CD3 (mAb 145-2C11) and anti-CD28 (mAb 37.51) antibodies, control hamster IgG, 
PE-labeled anti-Thy1.2, anti-CD8 and anti-CD44 antibodies were purchased from 
eBioscience (San Diego, CA). Goat anti-hamster IgG was purchased from Pierce 
(Rockford, IL). Anti-NFAT1, anti-NFAT2 antibodies were from Affinity Bioreagents 
(Golden, CO). Anti-PLC, anti-phospho- PLC (Y783), anti-ERK1, anti-phospho-ERK1 
(E10), and anti-c-Fos antibodies were from Cell Signaling Technology (Danvers, MA). 
Anti-α tubulin antibody was from Sigma- Aldrich (St.Louis, MO). Anti-c-Jun, anti-
phospho c-Jun (KM-1) and anti-actin antibodies were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA).  HRP-conjugated anti-mouse IgG and anti-rabbit IgG 
were from Bio-Rad (Richmond, CA).  The H-2Kb restricted 2C TCR- reactive peptide 
SIYRYYGL was purchased from NeoMPS (San Diego, CA). JNK inhibitor (SP600125) 
and the p38 inhibitor (SB203580) were purchased from BIOMOL International, L.P, 
(Plymouth Meeting, PA). Leptomycin B was purchased from Sigma-Aldrich. 
 
2.2 Animals  
 
2C TCR-Tg/RAG2-/- mice express the 2C αβ T cell receptor specific for the Ld MHC 
class I receptor [112] and were maintained on a mixed 129/C57BL/6 background.  
C57BL/6J mice (6-8 weeks old) were purchased from The Jackson laboratory (Bar 
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Harbor, ME). All mice were maintained in ventilated M.I.C.E. microisolator cages 
(Animal Care Systems, Littleton, CO) in the University of Maryland animal facility 
(College Park, MD). Animals received humane care in compliance with the “Guide for 
the Care and Use of laboratory Animals” published from the National Institute of Health 
(Bethesda, MD).  
2.3 In vivo anergy induction 
 
Mice were injected intraperitoneally (i.p.) with 25-50 nmol of the 2C peptide 
(SIYRYYGL) in sterile PBS or PBS alone. For single injections, spleens were harvested 
seven days after administration. For double injections, mice were injected on day 1 and 
day 5 and spleens were harvested on day 12. T cells were purified and tested for 
proliferation and cytokine secretion. 
  
2.4 Cell culture 
 
All cells were maintained in RPMI1640 medium (Mediatech, Herndon, VA) 
supplemented with 10% FBS (Hyclone, Logan UT), 2mM glutamine, 
penicillin/streptomycin, 10mM HEPES buffer, MEM non-essential amino acids, and 55 
M 2-mercaptoethanol at 37°C in a 5% CO2 atmosphere.  
 
2.5 T cell purification   
 
Murine T cells were purified from the spleens using the SpinSep or EasySep negative-
selection system (Stem Cell Technologies (Vancouver, British Columbia, Canada). 
 
 52 
Spleens were harvested from mice and macerated in PBS+2% FBS. For some 
experiments, the brachial, inguinal and mesenteric lymph nodes were also extracted for 
purification and combined with spleens. The cell suspension was then filtered through a 
nylon mesh and centrifuged at 1500 rpm for 5 minutes at room temperature and the pellet 
after centrifugation was resuspended at a concentration of 100 x 106 cells/ml in PBS + 
2% FBS + 5% rat serum. Appropriate volumes of T cell enrichment cocktail were added 
to the cell suspension as per manufacturer’s protocol and incubated for 15 minutes at 
4°C. The enrichment cocktail contains a combination of biotinylated monoclonal 
antibodies against cell surface antigens on mouse cells of hematopoietic cells that are not 
of T cell origin (CD11b, CD19, CD45R, CD49b, and TER119). The cells were then 
incubated with Biotin selection cocktail for 15 minutes at 4°C. The Biotin cocktail 
contains two mouse antibodies against biotin and dextran respectively. These two 
antibodies are held in a tetrameric antibody complex by a rat anti mouse IgG1. The cells 
were then incubated for another 15 minutes at 4°C with a suspension of magnetic dextran 
iron particles that can bind to the biotin selection cocktail. The T cells were then purified 
from this suspension by centrifugation over a density medium (SpinSep) or by using 
magnetic separation of the unwanted magnetically labeled non-T cells (EasySep).    
 
2.6 Estimation of T cell purity by flow cytometry 
 
100µl of the enriched T cell suspension was incubated with 1ul of anti-Thy1.2-PE 
(20µg/ml) or 1µl of Rat IgG-PE, which was used as isotype control. After a 15-30 minute 
incubation at room temperature, 300µl of FACS buffer (1X PBS+1% FBS) was added to 
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each sample. The samples were then read for PE fluorescence on a FACScalibur flow 
cytometer. A successful T cell purification yielded ~90% pure T cells.  
 
2.7 Estimation of CD44 surface expression  
 
Anergic T cells and the control T cells from PBS injected mice were analyzed for CD44 
surface expression levels. 100µl of purified T cells were incubated with either 1µl of anti-
CD44-PE (200µg/ml) or 1µl of Rat IgG-PE. After incubation at room temperature for 15-
30 minutes and PE fluorescence was measured using the flow cytometer.  
 
2.8 Proliferation and cytokine assays using peptide and APC stimulation 
 
T cell proliferation was measured by stimulating the T cells with TCR specific 2C 
peptide and splenic cells that function as APCs. 2C peptide was resuspended in RPMI at 
a concentration of 400nM and titrated down the rows of a 96 well plate. The final 
concentration of 2C peptide antigen ranged from 200nM to 0.05nM. The last row 
contained no peptide and served as a control. Spleen cells were obtained as described 
above, and resuspended in RPMI at a concentration of 4x106 cells/ml. 50µl of splenic 
cells (APCs) were added to each row of the 96 well plates. The purified T cells were 
resuspended at a concentration of 1x106 cells/ml. 50µl of T cells (either from a PBS 
injected or a peptide injected mouse) was added to all the rows of the plate. The assay 
was done in triplicates for each peptide concentration. The cells were incubated at 37°C 
in a 5% CO2 atmosphere. Proliferation after 72 hours of stimulation in vitro was 
determined by [3H] thymidine incorporation. Cells were pulsed for the last 6-8h with 1 
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Ci/well of [3H] thymidine (MP Biomedicals, Solon, OH) and incubated at 37°C. The 
cells were then transferred to glass fiber filters with a 96-well cell harvester (Tomtec, 
Hamden, CT), and analyzed by liquid scintillation using a 1450 Microbeta Trilux 
scintialltion counter (Wallac, Turku, Finland). The counts per minute (c.p.ms) obtained 
for each well were then averaged for the triplicate samples and plotted against peptide 
concentrations to obtain a proliferation curve. Standard deviations were also determined 
for each sample using standard calculations.   
 
Cytokine assays were organized in parallel to proliferation assays. 500µl of peptide 
(400nM), 250µl of splenic cells (4x106/ml) and 250µl of purified T cells (1x106 cells/ml) 
were incubated together at 37°C in a 5% CO2 atmosphere for 24-36 hrs. The supernatants 
from these stimulations were stored and cytokine concentrations were analyzed by 
ELISA. 
2.8.1 Proliferation assays using splenic cells 
 
Splenic cells were isolated from mice as described above. The spleen consists of both T 
cells and other antigen presenting cells such as dendritic cells that provide costimulatory 
cues for T cell activation. The cells were resuspended in complete RPMI with added 
EGTA (600µM) or CSA (300nM). The proliferation assay set up was similar to the one 
described above using 2C peptide and spleen cells. Anti-CD3 antibody was titrated across 
the rows of a 96 well plate instead of the 2C antigenic peptide. Anti-CD3 concentrations 
ranged from 6.4ng/ml to 1µg/ml and were serially titrated down the rows. 100µl of 
2.5x106 spleen cells were added to each well and incubated at 37°C for 72 hours. The 
cells were pulsed with [3H] thymidine at a concentration of 1mCi/ well for the last 8 
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hours of incubation. The proliferative ability of the cells were then measured as the c.p.m 
generated by the radioactive thymidine integrated into the DNA of the dividing cells and 
measured as described above.  
2.9 Enzyme linked immunosorbent assay (ELISA) 
 
IL-2 and IFN- levels in 24 or 36 hour stimulation supernatants were determined using a 
sandwich ELISA. Primary and biotinylated secondary anti-cytokine antibodies and 
recombinant cytokine standards were purchased from eBioscience (San Diego, CA) and 
used at the concentrations recommended by the manufacturer (Table 1). Alkaline 
phosphatase-conjugated avidin was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA) and used at a 1:3000 dilution. Colorimetric alkaline 
phosphatase substrate was purchased from Sigma-Aldrich (St.Louis, MO) and used at 1 
mg/ml in 10% diethanolamine buffer. Quantification was performed on a Versamax 
spectrophotometer (Molecular Devices, Sunnyvale, CA). Data were analyzed using 
Softmax Pro software (Molecular Devices). Data points for all analyses are presented as 
the mean of triplicate wells ± S.D. 
 IL-2 IFNγ 
Standards 20ng/ml – 0.3125ng/ml 100ng/ml – 1.5625ng/ml 





Table1: Concentrations of standards, primary and secondary antibodies used for 




2.10 T cell stimulation  
 
T cells were stimulated with anti-CD3 and anti-CD28 antibodies. The cells were first 
incubated with anti-CD3 and anti-CD28 antibodies (10g/ml) on ice for 30 minutes. For 
unstimulated controls, cells were incubated with Syrian hamster IgG and Armenian 
hamster IgG control antibodies. 5ml ice cold PBS was added to the samples and 
centrifuged for 5 minutes at 1500 rpm at 4°C. The supernatant was discarded and the 
pellets were resuspended in complete RPMI. The samples were then stimulated for 
appropriate time points with goat anti-hamster IgG as a secondary cross linking antibody 
(10g/ml) at 37°C. The stimulation was stopped at the different time points by addition 
of ice cold 1X PBS to the samples and transferring the samples to 4°C. The samples were 
then centrifuged at 4°C for 5 minutes at 1500 rpm and the pellet used for further analysis. 
2.10.1 T cell stimulation with anti-CD3 and anti-CD28 coated beads 
 
For some experiments T cells were stimulated with magnetic beads that were conjugated 
with anti-CD3 and anti-CD28 antibodies. Purified T cells were mixed with beads in the 
ratio of 1:3. The beads are magnetic and therefore can be separated from the solvent 
using a magnet. The beads were washed with 1X PBS and resuspended in RPMI. Once 
the cells were mixed with the beads, they were centrifuged at 1500 rpm for 5 minutes at 
4°C. Without removing the supernatant, the samples were then stimulated at 37°C for 
appropriate time points. The stimulation was stopped by transferring the samples to 4°C 
and adding 5ml of ice cold PBS. The cells were then centrifuged again, for 5 minutes, at 
1500 rpm at 4°C and the pellet was used for further analysis. Unstimulated samples were 
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generated by incubating T cells with beads coated with Syrian and Armenian hamster 
IgG antibodies. 
2.10.2 Linkage of anti-CD3 and anti-CD28 antibodies to tosyl activated beads 
 
Anti-CD3 and anti-CD28 antibodies were coupled to tosyl activated magnetic beads as a 
means of crosslinking the antibodies when they bind to CD3 and CD28 molecules on the 
T cell surface. Beads or antibody coated beads can be separated from the suspension 
buffer by magnetic separation. 75µg/ml anti-CD3 and anti-CD28 antibodies were added 
to 4x108 beads/ml and incubated at 37°C for 24 hours in 0.1M borate buffer (pH 9.5). 
The beads were then washed twice at 4°C with 1X PBS+ 0.1% BSA for 5 minutes each at 
4°C and the washed in 0.2% Tris (pH 8.5) with 0.1% BSA for 24 hours at room 
temperature.  The Tris buffer is used to inactivate the unoccupied tosyl groups that have 
not bound to the antibodies. Antibody coated beads were then separated from the buffer 
by magnetic separation and resuspended at a concentration of 4x107 beads/ml in 1X PBS 
+ 0.1% BSA. 0.02% NaN3 is added to prevent bacterial contamination. Beads coupled to 
Syrian and Armenian hamster IgG were generated similarly. 
 
2.11 Western blots 
 
The T cells were stimulated and lysed in RIPA buffer (1% NP-40, 0.5% sodium 
deoxycholate,0.1% SDS, 10 mM NaF, 1 mM Na3VO4 in PBS)  The lysates were resolved 
on a 8% or a 12% SDS PAGE gel (~1.25 x10 6 cells/sample) and transferred onto 
nitrocellulose membrane. The blots were blocked with 5% non-fat dry milk in PBS/0.1% 
Tween-20 (PBS-T) and probed with primary antibody (in PBS-T) at specified 
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concentrations, followed by HRP conjugated anti rabbit and anti mouse IgG respectively. 
The bands were visualized with SuperSignal West Pico Chemiluminescent substrate 
(Pierce).  
 
2.12 Measurement of intracellular calcium 
 
The intracellular calcium flux was measured by flow cytometry using the calcium 
sensitive dyes Fluo3 and Fura Red (Molecular Probes). Fluo-3 fluorescence at 530 nm 
increases with increasing Ca+2 binding, whereas Fura Red fluorescence at 670 nm 
decreases with increasing Ca+2 binding, allowing ratiometric measurement of calcium 
[113]. Purified T cells were resuspended in RPMI 1640 medium supplemented with 1% 
FBS at a concentration of 5x106/ml.  Cells were stained with 4 µM Fluo3, 10 µM Fura 
red and co-incubated with 10µg/ml anti-CD3 antibody and PE-labeled anti-CD8 for 30 
minutes at 30°C. The cells were then washed in RPMI with no additives and centrifuged 
at room temperature for 5 minutes at 1200 rpm. The pellet was then resuspended in 
incomplete RPMI at a concentration of 2x106  cells/ml.  The Fluo3/Fura red fluorescence 
values were then read on a FACSCalibur flow cytometer (Beckton Dickinson, Mountain 
View, CA). 300µl cell suspension was added to 900µl of prewarmed RPMI and the basal 
Fluo-3 and Fura Red fluorescence levels were measured for 60 seconds, after which 
300µl of cells were transferred to pre-warmed (37°C) RPMI (900µl) containing 7.5 g/ml 
goat anti–hamster IgG to crosslink the TCR/CD3 complex. The increase (Fluo3) and 
decrease (Fura Red) in fluorescence levels were then recorded for at least 500 seconds, 
collecting approximately 100 events per data point using CellQuest software (Beckton 
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Dickinson) The relative calcium concentration inside the cell was then plotted as a ratio 
of Fluo3 to Fura Red emission values using FlowJo software (Treestar, Ashland, OR). 
2.12.1 Measurement of calcium in the presence of EGTA  
Cells were stained as described above and resuspended in incomplete RPMI at a 
concentration of 2x106  cells/ml. The basal Fluo3 and Fura red fluorescence values were 
measured for 60 seconds, then the cells were transferred to pre-warmed RPMI that 
contained 7.5µg/ml secondary crosslinking antibody and required concentrations of 
EGTA for the total volume. The fluorescence values after activation were then measured 
in the presence of EGTA  
2.12.2 Measurement of calcium in the presence of thapsigargin 
 
Cells were stained and Fluo3 and Fura red fluorescence levels were determined, as 
described above. After measuring basal fluorescence, cells were stimulated by the 
addition of 1µM thapsigargin, instead of secondary crosslinking antibody. Calcium flux 




T cells were stimulated with anti-CD3 and anti-CD28 antibodies. 1x106 cells/sample were 
incubated with anti-CD3 plus anti-CD28 (10 g/ml) in complete RPMI1640 medium on 
ice for 30 minutes. Cells were centrifuged at 4°C for 5 minutes at 1500 rpm and the pellet 
was resuspended in complete RPMI. Cells were stimulated using Goat anti-hamster IgG 
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(10µg/ml) at 37°C for appropriate times. Stimulations were stopped by addition of 5 ml 
of ice cold PBS. Cells were centrifuged for 5 minutes at 4°C at 1500 rpm  and samples 
were resuspended in 100 l of RPMI/BSA (RPMI1640, 10 mM HEPES, pen/strep. 0.6% 
BSA). Cells were plated on to the poly-L-lysine-coated microscope slides (Polysciences, 
Warrington, PA) and incubated on ice for 40 minutes. After aspirating the supernatant, 
the adhered cells were fixed with ice cold methanol for 15 minutes and washed once with 
ice cold 1X PBS. Cells were then blocked and permeablized with PB buffer (RPMI 1640, 
10%FBS, 0.05% saponin, 10 mM glycine, 10 mM HEPES) for 20 minutes. Cells were 
incubated with anti-NFAT1 or anti-NFAT2 antibody at 2 g/ml for one hour at 4°C. 
Cells were washed three times with PB buffer and incubated with 2 g/ml Alexa Fluor 
594-linked anti-IgG (Molecular Probes, Eugene, OR) in PB buffer for one hour in the 
dark. After three washes in PB, cells were incubated in 1 M SYTO13 (Molecular 
Probes, Eugene, OR) in PB buffer for 20 minutes in the dark. Cells were post fixed in 4% 
paraformaldehyde and coverslips were then fixed on to the slides. The cells were viewed 
using a LSM 510 microscope (Carl Zeiss Microimaging, Thronwood, NY). For 
experiments done with specific treatments, cells were incubated with specific 
concentrations of EGTA, BAPTA, CSA, SP600125 (200µg/ml), SB203580 (20µg/ml) 
during the initial 30 minute incubation at 4°C with anti-CD3 and anti-CD28 antibodies. 
The cells were also maintained in RPMI-BSA containing the appropriate concentrations 
of the reagents during stimulation at 37°C. For leptomycin treatment experiments, cells 
were incubated with 200nM leptomycin for 30 minutes at 4°C before addition of anti-
CD3 and anti-CD28.  Cells were maintained in 200nM leptomycin containing RPMI-
BSA during stimulation for appropriate time points. 
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Quantification of nuclear localization was done using the ImageJ software package from 
NIH, using the colocalization macro. Two points were considered colocalized on the 
overlay, if their respective individual intensities were higher then the threshold and if the 
ratio of intensity is higher than the ratio calculated for the two channels of detection of 
fluorescence. The relative colocalization quantification for an individual cell was the 
cumulative score of all its colocalization points. The relative concentration of NFAT in 
the nucleus was then correlated with the strength of the intensity 
 
2.14 Intracellular staining for phospho c-Jun  
 
Naïve T cells were stimulated for appropriate time points by first incubating them with 
anti-CD3/anti-CD28 antibodies and then secondary crosslinking antibodies in the 
presence or absence of varying concentrations of the JNK inhibitor SP600125. After 
stimulation, each sample of 1x106 cells was fixed in 100µl of 2% formaldehyde in PBS 
for 20 minutes at room temperature. The cells were then washed twice with 500µl of 
0.03% saponin in PBS by centrifuging at 1500 rpm for 5 minutes at 4°C. The pelleted 
cells were then incubated with primary anti- phospho c-Jun antibody in 100µl of 1XPBS 
containing 10% normal rat serum (NRS) and 0.3% saponin. NRS or normal rat serum 
functions as a blocking agent, while saponin permeablizes the cell membrane. After 30 
minutes incubation at 4°C, the cells were washed as indicated above and incubated with 
secondary biotinylated anti-mouse IgG. All antibodies were resuspended in 1X PBS that 
contained 10% NRS and 0.3% saponin and incubations were for 30 minutes at 4°C. The 
cells were washed twice by centrifugation, as described above, between every incubation. 
After incubation with secondary antibody, the cells were incubated with PE conjugated 
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streptavidin. After another 30 minute incubation, the cells were washed once in PBS + 
0.03% saponin and once in FACS buffer (1X PBS + 1% BSA), and resuspended  in 300µl 
FACS buffer. The PE fluorescence that corresponds to phosphorylated c-Jun was then 
measured by flow cytometry.  
 
2.15 RNA isolation  
 
T cells were stimulated for appropriate times (resting, 3, 8 and 24 hours) with anti-
CD3/anti-CD28 conjugated beads. After stimulation the cells were centrifuged at 1500 
rpm for 5 minutes at 4°C and the pellet stored at -80°C. RNA from the cell pellets was 
purified using the Total RNA isolation Nucleospin RNA II kit from Macherey-Nagel 
(Bethlehem, PA) following manufacturer’s instructions. The purified RNA was 
quantified and 150-200ng of RNA from each sample was used to generate cDNA using 
reverse transcriptase using the iSCRIPT cDNA synthesis kit from Biorad ( Hercules, 
CA). 150-200ng of RNA from each sample was added to 4µl 5X iScript reaction mix and 
1µl iScript reverse transcriptase and DEPC RNAse free water to make up a final volume 
of 20µl. The reverse transcription reaction was performed at 25°C for 5 minutes, 42°C for 
30 minutes and 85°C for 5 minutes. cDNA was then used in regular PCR using primers 
specific for IL-2 (forward primer: 5’TGCTCCTTGTCAACAGCG 3’, reverse primer: 
5’TCATCATCGAATTGGCACTC 3’) at a melting temperature of 58°C and 18sRNA 
(forward primer: 5’ATGCGGCGGCGTTATTCC 3’, reverse primer: 
5’GCTATCAATCTGTCAATCCTGTCC 3’) at a melting temperature of 55°C. 
Reactions were performed for 35 cycles. The PCR DNA products were then analyzed on 





All statistical analyses were performed using GraphPad Prism verion 5. The minimal 
level of confidence at which experimental results were considered significant was 
p<0.05. Statistical significance between proliferation of responsive and anergic T cells or 
cells stimulated in the presence of various treatments, over concentration of 2C antigenic 
peptide or concentration of anti-CD3 antibodies was determined by two-way ANOVA 
followed by the Bonferroni post test analysis. Statistical significance between cytokine 
production of responsive and anergic T cells, or cells stimulated in the presence of 
various treatments was determined by the non-parametric two-tailed T test, followed by 
the Bonferroni post test analysis. Statistical significance between nuclear colocalization 
of NFAT1 and NFAT2, or between responsive and anergic T cells was determined by 



















Anergy, or T cell hyporesponsiveness, is a mechanism of peripheral tolerance in response 
to self-antigens that is seen in both CD4+ and CD8+ T cells. Reduced proliferative 
capability and decrease in IL-2 production are the hallmarks of an anergic phenotype. 
There is significantly less information about the effects of anergy induction on the other 
effector functions of tolerant T cells. IFNγ production is found to be variable in different 
models of anergy. In CD8+ T cells, the anergic T cells appear to retain some cytolytic 
ability, even though proliferation is affected [114]. T cell anergy is essentially a two-
phase process. Initially, an  tolerogenic stimulus results in the programming of the naïve 
T cells to be come anergic, which is then manifested when these T cells are introduced to 
a secondary stimulus. Incomplete activation of T cells or TCR stimulation in the absence 
of accompanying positive costimulatory cues is the most prevalent and accepted model of 
anergy induction [115]. The upregulation of certain genes during TCR stimulation alone, 
is responsible for the establishment of the hyporesponsiveness to restimulation [83]. The 
second phase or the establishment of the anergic phenotype is characterized by a number 
of signaling alterations downstream of TCR engagement. This dichotomy in the induction 
phase and the manifestation phase has been an area of intensive study, in both CD4+ and 




Many models have been used to mimic the incomplete activation of naïve T cells in a 
tolerogenic setting [116]. It has been difficult to categorize these models of anergy into 
distinct classifications, as the various anergy induction regimes appear to result in slightly  
different phenotypes. A broad categorization has been attempted by Shwartz et al, 
wherein the in vitro models of incomplete T cell activation leading to hyporesponsiveness 
have been termed clonal anergy, while the establishment of a pool of antigen specific 
anergic T cells in vivo by antigenic persistence leading to desensitization has been termed 
adaptive tolerance [92]. These include models where TCR transgenic T cells are 
adoptively transferred into animals that express their cognate antigen endogenously, or 
when cognate peptide is administered to animals that are transgenic for the peptide-
specific TCR. Anergic cells generated in response to  either set of  tolerizing stimuli, both 
in vitro and in vivo, display notable signaling alterations in proximal signaling events 
immediately after TCR engagement, that leads to a distorted immune response [117].  
 
In an adoptive transfer model of anergy induction in  T cells, where pigeon cytochrome C 
(PCC) specific T cells were transferred into mice expressing PCC under the control of a 
MHC class I promoter, Chiodetti et al. [118] reported a decrease in the tyrosine 
phosphorylation levels in tolerant T cells that are restimulated  in vitro. Specifically, 
ZAP70 and PLCγ, proteins that are activated immediately downstream of TCR 
engagement, display impaired phosphorylation. Corresponding to the decreased 
phosphorylation of PLCγ, tolerant T cells displayed an impaired calcium response. The 
MAP kinase pathway appeared to be only moderately affected in these cells. In another 
peptide injection model of in vivo anergy [119] where PCC TCR transgenic mice 
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wereimmunized with PCC peptide, impaired phosphorylation of the adaptor protein LAT 
was the main defect detected.  LAT is an adaptor protein that is phosphorylated by 
ZAP70 and acts as a scaffold for other critical signaling molecules such as PLCγ, Grb2 
and PI-3K. Anergized cells displayed reduced localization of LAT to the immune 
synapse that resulted from a decrease in palmitoylation and phosphorylation. 
Palmitoylation is required for localization of LAT to the lipid rafts of the immunological 
synapse, and a decrease in overall palmitoylation was reflected in impaired downstream 
signaling. Anergic cells also displayed reduced PLCγ phosphorylation. In an in vitro 
model, T cells treated with the calcium ionophore ionomycin display an unresponsive 
phenotype to further restimulation [120], and are defective in IL-2 production. This 
method of anergy induction has been used by a number of studies to identify the 
signaling alterations in the anergized cells. The signaling alterations described above 
were also detectable in T cells anergized in vitro using ionomycin [119]. 
 
The in vivo administration of the superantigen staphylococcal enterotoxinB (SEB) has 
also been reported to induce  CD4+ T cell hyporesponsiveness [96]. SEB administration 
leads to an initial large scale clonal expansion of the SEB reactive T cells bearing Vβ8 
containingTCR. This is followed by death of most of the T cells by apoptosis, resulting in 
a stable pool of anergic T cells. These surviving hyporesponsive T cells display defective 
phosphorylation of PLCγ and a corresponding defect in intracellular calcium 
mobilization. The MAP kinase pathway appears to be intact in these anergic T cells, 
suggesting that superantigen induced anergy was regulated mainly by a blockade of 
calcium signaling. These results were strengthened by the observation that SEB 
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administration did not lead to anergy in T cells which expressed a constitutively active 
form of calcineurin. Zu et al. further identified that anergic T cells generated by SEB 
administration had increased expression levels of CTLA-4 that might contribute to the 
anergic phenotype[121].  
 
The above studies demonstrate that anergic T cells display significant defects in proximal 
signaling events that result in defective calcium signaling spanning both in vitro and in 
vivo models. There are a number of studies that have found no detectable defects in 
events that regulate calcium influx, but instead have shown significant MAP kinase and 
Ras signaling defects in anergic T cells. In vitro anergy induction of A.E7 T cells ( CD4+ 
T cell clone) using plate bound anti-TCRβ displayed marked decrease in ERK 
phosphorylation and defective NF-κB mobilization to the nucleus, while the calcium 
signal cascade was unaffected [118]. Fields et al.[122] also reported defective ERK 
signaling corresponding to altered Ras signaling in pGL10 T cells (another CD4+ T cell 
clone), when anergized by plate bound anti-CD3 antibodies. Yet another model of in 
vitro anergy, where A.E7 cells were tolerized by antigen pulsed splenic APCs,  also 
reported that the anergic cells displayed a decrease in the inducible expression of the 
components of AP-1, that is regulated by MAP kinase activation [123].  
 
Oral tolerance is a systemic antigen induced T cell anergic state achieved by oral 
administration of the antigen in tolerizing conditions. This system is highly 
physiologically relevant, as this is a mechanism by which innocuous food antigens are 
tolerated by the immune system.  The signaling alterations in orally tolerized T cells were 
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studied in an OVA specific TCR Tg  model, where the mice were fed OVA protein as 
part of the diet [124]. The anergic CD4+ T cells obtained from these mice displayed 
overall decreased tyrosine phosphorylation, compared to naïve T cells. Specifically, 
ZAP-70, TCR-ζ, LAT and PLCγ were found to be hypo-phosphorylated after in vitro 
stimulation. This corresponded with impaired calcium mobilization and decreased 
NFAT1 nuclear localization. The MAP kinase pathway was unaffected. Interestingly, it 
was found that orally tolerized cells displayed impaired degradation of the cell cycle 
inhibitor p27KIP1, compared to naïve T cells.  T cell anergy induced by oral administration 
of antigen therefore displays a combination of characteristics of other types of in vitro 
and in vivo anergy described here.  
 
The above examples illustrate the various signaling defects that have been reported in 
anergic CD4+ T cells (Figure 3.1). CD4+ and CD8+ T cells share the basic signaling 
machinery that is activated by stimulation. Also, both peripheral CD4+ and CD8+ T cells 
require IL-2 as their cytokine stimulus for proliferation and expansion. However, a strict 
extrapolation of CD4+ based results into the CD8+ system might miss CD8+-specific 
phenomena.  CD8+ T cells are known to have more stringent requirements for activation, 
and do not appear to be as dependent on CTLA-4 for anergy induction [125]. 
Nevertheless, results garnered from CD4+ trials of anergy provide an important 
comparison for analyzing features of CD8+ T cell anergy. A number of groups have 
focused specifically on CD8+ T cell anergy. Just as the study of the various models of 













































Figure 3.1: Signaling alterations in anergic T cells upon restimulation. Induction of 
anergy in primary murine T cells results in multiple signaling modulations in the cells, 
upon secondary stimulation, consisting of both signal1 (TCR engagement) and signal2 
(positive costimulation). Anergic cells display a decrease in cellular tyrosine 
phosphorylation levels, specifically, the ITAM motifs in the cytosolic regions of the  
chain component of the TCR,  ZAP-70, the adaptor protein LAT, and PLC 
phosphorylation are affected. Palmitoylation of LAT, required for membrane recruitment 
is also decreased. Intracellular mobilization of calcium has also been found to be 
detectably impaired in anergic T cells. NFAT1 nuclear translocation that is mediated by 
calcium signaling is also impaired in these cells. Decrease in DAG levels leading to 
impaired Ras signaling has been reported in some models. Defective Ras signaling results 
in the impaired organization of the transcription factor AP-1 that participates in IL-2 
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transcription. NF-κB nuclear translocation mediated by events downstream of PI-3K and 
PKCθ signaling is also affected in certain models of anergy. This is a composite look at 
the possible signaling alterations that define an anergic phenotype. As has been 
described, anergic T cells that have been tolerized by different modes of induction show 





















variability in the signaling changes reported for the various anergy models in CD8+ T 
cells. 
 
Dubois et al. [126] characterized the proliferative and signaling features of anergic T cells 
using the F5 (influenza NP366-374/Db) TCR transgenic mice in a RAG knockout 
background. In vivo anergy was established by peptide injections delivered in the 
absence of adjuvants. They observed that the anergized cells displayed a partial block in 
the proximal tyrosine phosphorylation events, including ZAP70 and PLCγ. These cells 
also displayed reduced calcium flux. The MAP kinase pathway and phosphorylation of 
important molecules such as ERK was not examined in this model. A study with a similar 
model of in vivo anergy, using the 2C TCR Tg T cells, found that defective Ras signaling 
and resultant impaired MAP kinase activation were the main signaling defects displayed 
by the anergic T cells. The transduction of constitutively active Ras rescued MAP kinase 
activation and IL-2 production in these cells, preventing them from undergoing anergy 
[127].  
 
Frauwirth et al.  have previously described a model of in vivo induction of anergy in 
CD8+ TCR transgenic mice, using intraperitoneal (i.p.) injection of the 2C antigenic 
peptide in the absence of adjuvants to tolerize the T cells [125]. T cells recovered from 
peptide injected mice showed reduced proliferation in response to restimulation with 2C 
antigenic peptide and a corresponding reduction in expression of IL-2. These cells were 
antigen experienced and had undergone at least one round of cell cycle progression, as 
seen by upregulation of CD44 surface expression and increased cyclin D and E 
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expression (K. A. Frauwirth, unpublished observations). I investigated the signaling 
























3.2.1 Intraperitoneal administration of 2C peptide induces anergy 
 
2C TCR transgenic mice on a RAG deficient background were used to obtain 
homogenous pools of transgenic T cells. Mice were injected with 2C antigenic peptide 
resuspended in sterile PBS. The control animals were injected with sterile PBS alone. 
Seven days after the final injection, the T cells were purified from the spleens of the test 
and control animals. CD44 is a T cell surface protein upregulated upon TCR engagement; 
therefore CD44 surface expression was determined in T cells from peptide injected mice. 
Surface expression of CD44 was elevated in the T cells from peptide injected mice 
(Figure 3.2A), confirming that the T cells from peptide injected T cells were antigen 
experienced and not naïve. T cell anergy has been characterized by reduced proliferation 
and cell expansion to restimulation. To determine the proliferative ability of the T cells 
from peptide injected mice, cells from both the test pool and control pool were stimulated 
in vitro for 72 hours in the presence of splenic cells (APCs) and graded concentrations of 
TCR specific 2C peptide. Proliferation was determined by the amount of [3H] thymidine 
present in the cells. T cells from peptide injected mice displayed strongly reduced 
proliferation compared to the control cells (Figure 3.2 B).  
 
Anergic cells also display an altered cytokine profile compared to completely activated T 





















































Figure 3.2: Figure 1. T cells from peptide injected mice are anergic. T cells were 
purified from PBS and peptide injected mice. A. Analysis of surface expression of CD44 
for T cells from peptide and control mice. 1x106 cells were incubated with anti-CD44-PE 
antibody and surface expression was determined by flow cytometry. As negative control, 
cells were also incubated separately with Rat IgG-PE antibody (isotype control). B. In 
vitro proliferation measurements for splenic T cells purified from PBS and peptide 
injected mice. T cells (5x104) were stimulated with graded concentrations of peptide in 
the presence of splenic APCs for 72 hours at 37°C. [3H] Thymidine was added to the 
cells during the last 8 hours of stimulation. Proliferation was assayed by [3H] thymidine 
uptake in the cells. Shown are combined averages (±s.d.) from three independent 




















































































































































































Figure 3.3: IL-2 production is decreased in T cells from peptide injected mice. T 
cells were purified from PBS and peptide injected mice. Cytokine production in these 
cells was determined by ELISA and mRNA analysis. A, IL-2 secretion in purified T cells 
was determined by sandwich ELISA. 1x106 T cells were stimulated with 100nM 2C 
peptide and 4x106 splenic APCs for 24 hours, and the supernatants were used for ELISA 
analysis. Displayed are combined averages (± s.d.) from three independent experiments 
conducted in triplicate. **, p<0.01 B. IL-2 expression was also analyzed by mRNA 
analysis. Purified T cells (5x106  cells) were stimulated with anti-CD3/anti-CD28 coupled 
beads for 3,8 and 24 hours, or left unstimulated. Total RNA from these samples were 
then reverse transcribed to generate cDNA, which was then analyzed by PCR for IL-2 
expression using IL-2 specific primers. Shown is a representative result of two 
independent experiments. C. IFNγ secretion from T cells purified from PBS and peptide 
injected mice was analysed similar to IL-2. Shown are combined averages (± s.d) from 












expansion in activated T cells, is upregulated after complete stimulation. T cells from 
peptide injected mice display ~80% reduction in IL-2 secretion (as determined by 
ELISA), upon in vitro stimulation for 24 hours. The expression profile of IL-2 mRNA 
also mirrored secretion, with cells from peptide injected mice expressing minimal to no 
IL-2 mRNA, upto 24 hours after stimulation. Thus, the systemic administration of TCR-
specific, sterile antigenic peptide induces anergy in 2C TCR transgenic CD8+ T cells.  
 
IFNγ is an important effector cytokine that is upregulated in activated CD8+ T cells. This 
cytokine is responsible for the differentiation of naïve CD8+ T cells into effector cytolytic 
cells (CTLs) and also has anti-viral properties.  Impaired upregulation of IFNγ has been 
seen in some, but not all models of anergy [2]. 2C T cells from peptide injected mice 
showed a moderate decrease in IFNγ levels as determined in cell supernatants obtained 
after stimulation for 24 hours. This indicates that anergy induced by i.p. injection of 
peptide differs from studies of anergy, in which T cells show markedly impaired IFN- 
responses [1, 92]. 
 
 
3.2.2 Intracellular mobilization of calcium is impaired in anergic T cells 
 
Anergic T cells have been found to display significant signaling defects, including 
impaired calcium signals. I determined the intracellular mobilization of calcium in 
anergic cells by measuring the fluorescence levels of the two calcium sensitive dyes 
Fluo3 and Fura red. Fluo-3 fluorescence at 530 nm increases with an increase in  Ca+2 
binding, whereas Fura Red fluorescence at 670 nm decreases with increasing Ca+2 
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binding, allowing ratiometric measurement of calcium [113]. Cells were loaded with 
these dyes and the fluorescence emission values were measured after stimulating the 
cells. Upon stimulation by crosslinking of CD3, the tolerant cells displayed a reduced 
calcium flux, although it was not completely abrogated (Figure 3.4 and Appendix). The 
anergic cells appeared to be less competently influxing calcium. The calcium response 
curve looked similar to naïve cells, but at a lower scale. Thus the anergic cells were not 
completely deficient in intracellular calcium, but fluxed reduced concentration of calcium 
that might inhibit or modify downstream signaling events. This is consistent with the 
observation of Dubois et al. in a similar peptide injection system, but using the F5 TCR 
transgene [126]. Thus, defective calcium signaling may be an important component of 
peptide-induced in vivo anergy in CD8+ T cells. 
 
Calcium signaling in T cells is biphasic. The release of endoplasmic reticulum (ER) 
calcium activates surface calcium release-activated calcium (CRAC) channels, causing a 
large influx of extracellular calcium. These phases occur in rapid succession, but can be 
resolved by chelating extracellular calcium with EGTA. Crosslinking the TCR of naïve T 
cells in the presence of EGTA produced a small rise in intracellular calcium (Figure 3.5), 
a result of ER calcium release. The rise in anergic T cells was comparable to that in naïve 
cells, but occurred more slowly. When extracellular calcium was restored, I still saw a 
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Figure 3.4: Anergic CD8+ T cells display a calcium signaling defect.  Anergic and 
naïve T cells were loaded with Fluo3 and Fura Red, and intracellular calcium responses 
to anti-CD3 and secondary crosslinking antibody stimulation were determined by flow 
cytometry. The basal fluorescence levels of Fluo3 and Fura red in the cells were 
measured for the first 60 seconds, before addition of the stimulatory crosslinking anti-
hamster IgG antibody.  A. The increase in Fluo3 fluorescence levels upon stimulation 
was measured. B. The decrease in Fura red fluorescence levels upon stimulation was 
measured. C. Intracellular calcium responses to anti-CD3 stimulation were depicted as a 
ratio of Fluo3/ Fura Red fluorescence. Shown above are the averages of the Fluo3/Fura 
red ratio for all the cells at each time point.  D. Dot plot of Fluo3/Fura red ratio for 
responsive and anergic T cells from the experiment shown in C. Shown are representative 




















































Figure 3.5: Anergic T cells display defective intracellular calcium mobilization. ER 
store release of calcium in anergic T cells was measured by stimulation in RPMI 
containing 2 mM EGTA. After 60 seconds of measuring the basal fluorescence levels of 
Fluo3 and Fura red, cells were stimulated by anti-CD3 and secondary crosslinking 
antibody stimulation. After ~ 200 seconds of stimulation, 3 mM CaCl2 was added to 
replenish the extracellular calcium source. Calcium flux was measured as in Figure 3.4. 







3.2.3 Defective phosphorylation of PLCγ in anergic cells.  
 
Since ER calcium release was altered in anergic T cells, we examined the activation of 
PLC, an upstream inducer of calcium release. The activation of PLCγ is an important 
event following T cell stimulation, as it enables calcium signals and resultant NFAT 
activation, which contributes to the transcriptional regulation of the activated T cells. We 
determined the activation of PLCγ in CD8+ anergic cells, to determine if the defect in 
calcium signaling seen, can be attributed to PLCγ based signaling alterations. Complete 
activation of PLC requires phosphorylation at Y783, which was detected using a 
phospho-specific antibody. As shown in Figure 3.6 A, TCR-induced phosphorylation of 
PLC in anergic T cells was impaired compared to naïve T cells. PLCγ phosphorylation 
is a proximal signaling event following TCR engagement and has been shown to peak 
within the first fifteen minutes after stimulation. Total PLC levels remained stable for at 
least 30 minutes in both responsive and anergic cell lysates (Figure 3.6 B), indicating that 
the impaired phosphorylation is not a result of proteolytic degradation of PLC. 
 
3.2.4 Calcium signaling in anergic cells is altered upstream of intracellular 
store release 
 
The modulations in calcium signaling in anergic cells could be either at the stage of 
release of calcium from ER, or during the subsequent capacitative influx of calcium 






































Figure 3.6: Anergic T cells display reduced phosphorylation of PLCγ. Responsive 
and anergic T cells were stimulated for the appropriate time points with anti-CD3/anti-
CD28 and secondary crosslinking anti-hamster IgG antibodies. The cells were then lysed 
using RIPA buffer, and lysates from equivalent cell numbers (~ 1x106 cells/sample) were 
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used for western blotting analysis. A. In vitro stimulated anergic and naïve T cell lysates 
were assayed for activation of PLC by Western blot for Y783 phosphorylation. As 
loading controls, the lysates were also assayed for total PLCγ levels. Shown are 
representative results of three independent experiments. B. Whole cell lysates from 
anergic and responsive T cells were assayed for total PLCγ levels using western blot 
analysis. As loading controls, lysates were also assayed for α-tubulin levels in each 




















could be entirely due to the proximal signaling defects or could be the cumulative effect 
of a number of defectively functioning signaling modules within the calcium signaling 
pathway. Recently it was observed that human peripheral T cells isolated from patients 
afflicted with an immune deficiency displayed a strong post ER defect in calcium 
mobilization, which affected the proliferation and cytokine production of these cells [55]. 
Since the phenotype of these cells resembles anergic T cells, we looked to see if CD8+ 
anergic T cells also displayed reduced calcium signaling after ER store release. To 
delineate between defects upstream of store release and post ER defects of calcium 
signaling, we measured calcium flux in anergic cells that were treated with thapsigargin. 
Thapsigargin is an inhibitor of the Sarco/ endoplasmic reticulum calcium ATPase 
(SERCA) that functions as a calcium pump on the ER [128]. Thapsigargin treatment 
depletes calcium stores in the ER, and inhibits refilling of the stores once calcium release 
is complete. This pharamacological inhibitor has often been used to trigger store release 
of calcium, bypassing TCR engagement and the initial proximal signaling events 
associated with TCR stimulation. Calcium signaling was initiated by treating anergic and 
control cells with thapsigargin in the presence of EGTA to chelate extracellular calcium. 
This resulted in complete emptying of the intracellular stores. When the calcium in the 
medium was replenished, there was an immediate elevation in the intracellular calcium 
levels due to the intense signal generated by thapsigargin treatment. Anergic cells and 
naïve T cells responded similarly to thapsigargin and displayed comparable calcium 
levels during the sustained response (Figure 3.7). Thus, defective calcium signaling in 
anergic CD8+ T cells can be attributed entirely to the defects in proximal signaling that 















































Figure 3.7: Defective calcium influx in anergic T cells is determined by signaling 
events upstream of ER release. A. Intracellular calcium influx after total ER release 
was measured by stimulating anergic T cells with thapsigargin. Fluo3 and Fura red 
loaded T cells were resuspended in RPMI supplemented with 2mM EGTA and stimulated 
with 1µM thapsigargin. After ~200 seconds of measuring Fluo3 and Fura red 
fluorescence values, 3mM CaCl2 was added to replenish extracellular calcium. As 
described above, calcium flux is depicted as a ratio of Fluo3/Fura red values. Shown is a 






Systemic administration of an antigenic peptide in the absence of any adjuvants results in 
the antigen specific T cells becoming refractory to further stimulation, even in the 
presence of complete costimulation. Abrogated production of the proliferative cytokine 
IL-2 leads to a decrease in large-scale clonal expansion in response to stimulation. These 
cells are not completely non responsive, however, as IFNγ production, is only partially 
reduced. This suggests that these cells still retain functional capability and could perform 
effector functions. These results were similar to another study, where anergy induction in 
CD8+ murine clones elicited normal expression of IFNγ [114]. Other models of in vivo 
induction of anergy in CD4+  cells  correlated with a significant reduction of IFNγ in the 
anergic cells [92], therefore it would be informative to determine if this characterestic is 
unique to CD8+ T cells and their functions.  
 
In order to better understand the induction of hyporesponsiveness in anergic T cells, I 
studied the signaling alterations of in vivo tolerized CD8+ 2C TCR-transgenic T cells. 
Two major signaling pathways frequently found to be altered in anergic T cells are the 
ras/MAPK cascade and calcium signaling [92]. Although I could not detect consistent 
defects in MAPK activation in our model of in vivo anergy induction, I found that 
calcium responses in anergic cells were blunted relative to naïve cells. This is consistent 
with multiple other in vivo anergy models, spanning different induction methods and 
both CD4+ and CD8+ T cells [96, 118, 126], suggesting that the calcium limitation is a 
common feature of in vivo T cell anergy. It is important to note that the Gajewski group 
works with the same transgenic mouse model (2CTCR Tg), and yet they have 
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consistently reported significant Ras-MAP kinase defects in cells anergized in vivo under 
similar conditions [127]. These paradoxical results might reflect the complexity of 
studying a physiological process such as anergy, which is a functional consequence of 
various alterations in the vast network of signaling cascades that interact with each other 
after T cell stimulation.  
 
An important initiating event of T cell calcium signaling is the activation of PLC [7, 
129]. In anergic 2C T cells, phosphorylation of PLC was partially inhibited, indicating 
reduced activation correlating with a slower release of ER calcium. It has been reported 
that degradation of PLC mediated by ubiquitin ligases, such as Cbl-b and gene related to 
anergy in lymphocytes (GRAIL), accounts for the reduction of calcium flux and 
subsequent functional defects in anergic T cells [107]. Examination of total PLC in 
anergic T cells from peptide injected 2C TCR-transgenic mice did not show degradation 
for at least 30 minutes after restimulation. Thus, reduction in PLC protein levels does 
not appear to be a significant contributing factor to the reduced calcium flux in this 
system. The degradation of PLCγ and PKCθ has been observed in cells that were 
anergized by ionomycin treatment and might be a peculiarity of that system. Also, 
expression analyses of these ubiquitin ligases have all been done in CD4+ models of 
anergy. It will be important to ascertain the expression profile of these anergy related 





The defect in mobilizing calcium in anergic cells has been solely attributed to the 
proximal signaling events that precede calcium entry. The decrease in PLCγ 
phosphorylation suggests a causal role in the impaired calcium mobilization into the 
cells. However, reduction in phosphorylation is not complete and the decrease in 
phosphorylation might not entirely explain the calcium signaling defect. IP3 generated by 
PLCγ activity binds to its receptor on the ER membrane, the IP3R, which also functions 
as the active calcium channel through which ER calcium is released. The tyrosine kinase 
Fyn, has been shown to phosphorylate the IP3R, and tyrosine phosphorylation on Fyn is 
upregulated upon T cell stimulation [30]. Phosphorylation of the receptor increases the 
open probability of the channel, and also aids in keeping the channel open, once cytosolic 
calcium levels start increasing, as the IP3R becomes inactive when it senses high 
concentrations of cytosolic calcium. Thus Fyn dependent phosphorylation of the receptor 
of IP3 might be an important regulatory mechanism to ensure sustained elevated calcium 
levels in activated T cells [130]. Experiments done to determine the phosphorylation 
patterns of the IP3R1 in anergic T cells were inconclusive due to technical difficulties. 
More sensitive assays such as microscopy to determine phosphorylation patterns of the 
receptor [130] might yield more information about the role of IP3-IP3R interactions in 
regulating calcium influx.  
 
 The multitude of altered signaling profiles that have been described by various studies 
highlights the variable biological states that T cells can exist in under different 
stimulation conditions. Antigenic conditions and the mode of induction of anergy 
therefore, play an important role in determining the constitution of the anergic state. This 
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will be highly relevant in physiological situations such as transplantation which use 






































4. Reciprocal NFAT1 and NFAT2 nuclear localization in 




An important downstream target of calcium signaling in T cells is the activation of the 
NFAT family of transcription factors. The large influx of calcium activates the 
serine/threonine phosphatase calcineurin that dephosphorylates serine residues on the 
regulatory domain of NFAT, leading to the movement of cytosolic NFAT into the 
nucleus, where activated NFAT enables transcription of the various NFAT- dependent 
genes [131]. NFAT also functions as a transcription repressor for certain genes [132]. In 
tandem, kinase molecules collectively referred to as the NFAT kinases rephosphorylate 
the serine residues to restore the cytosolic resting conformation of NFAT. The cellular 
localization and the activation state of NFAT are therefore mediated by a balance 
between these two events that are regulated by T cell activation. 
 
4.1.1 Calcineurin mediated dephosphorylation of NFAT 
 
Multiple serine residues are dephosphorylated in the NFAT regulatory domain by 
calcineurin. An important consequence of this is the exposure of the NLS,which leads to 
nuclear accumulation of NFAT [72]. This mechanism is common to NFAT 1-4 and has 
been widely targeted during immunesuppressive regimens by the use of CSA or FK506. 
Okamura et al.[73] determined that the serine residues were dephosphorylated in a 
specific order using a mass spectrometry based strategy, where phosphorylation sites in 
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an enzymatic digest of a protein are identified by mass spectrometry by the change in 
mass after dephosphorylation.  NFAT1 was shown to be phosphorylated at ~ 21 serine 
residues in resting cells. Of these, 18 were located in the regulatory region, and 14 of 
them are found in sequences conserved through the NFAT family. Upon stimulation, 13 
of these residues were dephosphorylated to result in complete exposure of the NLS and 
masking of the nuclear export sequence (NES). They showed that the SRR1 region is 
dephosphorylated first, resulting in partial unmasking of the NLS and in enhanced 
accessibility of calcineurin to the SPxx repeat motifs.  
 
Okamura et al.[73] also predicted a conformational switch model for the effect of 
dephosphorylation on the active and inactive conformations of NFAT. The active 
conformation is defined by complete dephosphorylation of the 13 serine residues and 
total uncovering of the NLS in all the NFAT molecules. On the other end of the 
spectrum, NFAT in the inactive confirmation consists of totally phosphorylated serine 
residues and a masked NLS. Progressive dephosphorylation therefore marks the 
intermediate stages which are associated with an increasing probability that any molecule 




The phosphorylation of residues in the transactivation domain has been shown to be 
necessary for the induction of transcriptional activity of NFAT.  This domain has binding 
sites for co-activators, such as p300 and cAMP response element-binding protein 
(CREB)-binding protein (CBP), that enhance transcriptional activity of NFAT. These 
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proteins act as histone acetyltransferases and regulate chromatin assembly, and therefore 
influence gene transcription. These proteins also recruit RNA polymerase and other 
components of the basal transcriptional machinery to aid in transcription [133] .  Various 
proteins such as p38 [134], PKCζ [135], Cot/Tpl2 [136] and Pim1 [137] can bind to the 
transactivation domain and initiate phosphorylation events that lead to higher 
transcriptional activity. In Jurkat T cells, p38 has also been shown to promote the binding 
of CBP to sites in the transactivation domain of NFAT2, an event required for NFAT 
activity [138]. These signaling events provide a potentially calcineurin-independent 
component of NFAT activation that acts in concert with the calcineurin mediated 
dephosphorylation processes to result in gene expression. It has not been entirely 
resolved if these events take place in the nucleus or in the cytoplasm and if the activating 
phosphorylation reactions precede or follow the dephosphorylation of residues in the 
regulatory domain. Also, the possibility of interdependence between these two processes 
needs to be investigated to obtain a complete picture of regulation of translocation and 
activation of NFAT in T cells. 
 
4.1.3 NFAT kinases 
 
The desphosphorylation and subsequent nuclear localization of NFAT is not irreversible. 
Intracellular kinase proteins collectively referred to as NFAT kinases rephosphorylate the 
serine residues that have undergone calcineurin phosphatase activity in order to restore 
NFAT to its resting conformation (phosphorylated). Therefore, the cellular location of 
NFAT in resting and activated cells is maintained by a balance between the phosphatase 
activity of calcineurin and the resphosphorylating activity of the NFAT kinases (Figure 
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4.1). These kinases act either in the cytosol, immediately after calcineurin activity, or in 
the nucleus to promote nuclear export. Some of these kinases also function as 
maintenance kinases, which retain NFAT in the cytosol in resting T cells.  These kinases 
can be pan-NFAT kinases that phosphorylate all members of the NFAT family, or can be 
member-specific, conferring distinct patterns of regulation. Casein kinase1 (CK1) is 
involved in the phosphorylation of the SRR-1 region of the regulatory domain of NFAT. 
CK1 binds NFAT at the amino terminal end at a sequence conserved in all the NFAT 
proteins. CK1 is bound to NFAT in resting cells and therefore maintains the cytosolic 
localization of NFAT in unactivated T cells [139]. Glycogen synthase kinase 3 (GSK3), 
another cytosolic NFAT kinase, requires priming of NFAT by the cAMP-dependent 
protein kinase (PKA). PKA phosphorylates both NFAT1[139] and NFAT2 [140] at serine 
residues in the SP2 motif, and the NLS, providing the  priming phosphates for subsequent 
phosphorylation by GSK-3 at the SP2 and SP3 repeat motifs. GSK-3 also functions as a 
maintenance kinase, retaining NFAT in the cytosol in resting T cells. GSK-3 activity is 
inhibited by Akt, which is activated downstream of CD28 signaling, and is therefore 
downregulated during T cell activation, tilting the balance toward calcineurin activity and 
nuclear accumulation of NFAT [141].  
 
Another family of NFAT kinases are the dual-specificity tyrosine-phosphorylation 
regulated kinases (DYRK) family proteins that phosphorylate the SP-3 motif of NFAT1 
[142]. These kinases were identified as part of a genome wide drosophila RNAi screen 
for NFAT regulators. DYRK2 is cytoplasmic and serves to maintain NFAT1 in the 















































Figure 4.1: Regulation of NFAT activation. Signals downstream of TCR ligation lead 
to the large influx of extracellular calcium. Calcium binds calmodulin and activates 
calcineurin. Activated calcineurin dephosphorylates NFAT, exposing the nuclear 
localization signal (NLS) on these proteins. This leads to the nuclear trafficking of these 
proteins via the importin machinery of the cell. Other molecules such as PKC, COT, 
PIM-1 and p38 (specific for NFAT2) phosphorylate specific residues in the 
transactivation domain of NFAT to further activate them.  In the nucleus, activated 
NFAT proteins bind to promoter/enhancer sequence of DNA to initiate transcription of 
various genes, either alone or by forming composite interactions with other transcription 
factors, such as AP-1. Coactivators of transcription such as CBP and p300 also bind the 
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transactviation domain of NFAT to aid in transcriptional initiation. NFAT nuclear 
localization is negatively regulated at various stages. The activity of calcineurin is 
negatively regulated by proteins such as CABIN-1, AKAP79 and the DSCR proteins, 
which bind calcineurin to inhibit enzymatic activity. Homer2/3 binds to NFAT at 
calcineurin recognition sites, opposing calcineurin binding. The NFAT kinases CK-1 and 
GSK-3 aid in maintaining NFAT in the phosphorylated state in the cytosol, or 
rephosphorylate serine residues in nuclear NFAT to expose the nuclear export sequence 
and aid in translocation out of the nucleus. DYRK-2 is a NFAT1-specific cytosolic 
NFAT kinase, while DYRK-1 promotes nuclear export. The MAP kinases p38 and JNK 
specifically phosphorylate nuclear NFAT1 and NFAT2 respectively, promoting export. 
NFAT regulation by signals downstream of CD28 activation is mediated by the negative 
regulation of Akt on Homer2/3 and GSK-3. NFAT 1/2 cellular localization and 
transcriptional activity is thus regulated by a network of signaling events, that are 











MAP kinases p38 [144] and JNK [145] act as NFAT1 and NFAT2 specific kinases, 
respectively. These proteins act on the SRR-1 region of the NFAT proteins and mediate 
nuclear export. JNK has also been shown to act on specific residues in the PxIxIT 
calcineurin docking motif of NFAT2 and prevents calcineurin binding to NFAT2 [146]. 
The presence of multiple pan-NFAT, and protein-specific NFAT kinases, reinforces the 
idea that regulation of cellular localization and transcriptional activation of the NFAT 
proteins is a complex network of signaling events that can mediate specificity and non-
redundancy.  
 
The cytosolic localization of NFAT in resting cells is maintained by a number of 
scaffolding proteins which act in tethering the NFAT proteins in the cytosol. Recently, 
the Homer proteins have been identified as inhibitors of calcineurin binding. These 
proteins interact with NFAT at regions corresponding to the calcineurin docking site, 
preventing calcineurin docking. Homer 2 and 3 have been shown to bind both NFAT1 
and NFAT2 in vitro in primary murine T cells,  and act as negative regulators of NFAT 
dephosphorylation [147]. Upon T cell activation, these proteins are negatively regulated 
by AKT to allow calcineurin binding and nuclear translocation. These scaffolding 
components, thus introduce another layer of complexity in the regulation of cellular 
trafficking of the NFAT proteins.  
4.1.4 NFAT signaling networks 
 
Although NFAT and MAP kinase signaling are usually presented as parallel and separate 
pathways, more and more proteins have been identified with multiple roles that have 
integrated these two cascades into a complex network of regulation of activation. The 
 
 100 
large influx of calcium mediated by TCR signaling, leading to calcinuerin activity, plays 
the central role in NFAT translocation and activity. However, both the MAP kinase 
pathway and signals downstream of the CD28 activation pathway have been implicated 
in the regulation of these events. The NFAT kinase GSK3 and the scaffolding proteins 
Homer2 and 3 are negatively regulated by Akt, a kinase activated downstream of CD28 
stimulation. The MAP kinases p38 and JNK play important roles as NFAT kinases that 
enhance nuclear export of NFAT proteins. CD28 and Grb-2 cooperate with Vav1 to 
upregulate NFAT/AP-1 mediated transcription [148]. PKCζ and Pim1, proteins that are 
activated by PI-3 kinase signaling, and p38, have also been implicated in phosphorylation 
of the transactivation domain to enhance transcriptional activity of NFAT. Thus the 
regulation of NFAT proteins in T cells is a complex network of positive and negative 
regulation, both in resting and activated T cells.  
 
NFAT proteins are early initiators of transcription, and therefore also contribute to 
regulation by transcribing proteins that feed back into the network. Carabin is one such 
negative feedback regulatory protein that binds to calcineurin and inhibits NFAT 
dephosphorylation [149].  The study of NFAT regulation, therefore, involves more than 
just the study of the role of calcium-calcineurin activity. Also, these regulatory 
mechanisms have been studied either using NFAT1 or NFAT2 as a representative of the 
NFAT family of proteins. Therefore, it is not known if these signaling events affect all 
the NFAT family members that are expressed in the cells that are studied, or if the effect 
is specific for the particular NFAT family member. Direct comparisons between NFAT1 
and NFAT2 to ascertain the result of any signaling modification is required to obtain a 
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more comprehensive measure of the regulation of NFAT, and the individual roles 
NFAT1 and NFAT2 play in T cell activation and anergy. 
 
Various studies have looked at defective NFAT nuclear translocation as a product of the 
impaired calcium response in anergic T cells [126, 150]. These studies have focused only 
on NFAT1 nuclear movement. In order to determine the cellular localization pattern of 
the NFAT family members in my model of anergy I analyzed the nuclear translocation of 
both NFAT1 and NFAT2 as a response to restimulation in CD8+ anergic T cells. NFAT1 
translocation into the nucleus was blocked in anergic T cells. Unlike NFAT1, NFAT2 
was rapidly translocated into the nuclei of anergic, but not responsive T cells. I also 
found that directly limiting extracellular calcium or calcineurin activity in normal T cells 
was sufficient to replicate the anergic T cell pattern of NFAT localization. This indicates 
that NFAT1 and NFAT2 are responsive to different cytosolic calcium levels, an 
observation that was previously unreported.  The reciprocal regulation of NFAT1 and 
NFAT2 suggests that while NFAT1 is the predominant isoform involved in a productive 












4.2 Results  
4.2.1 NFAT 1 translocation into the nucleus is inhibited in tolerant cells 
 
Calcium entry into T cells activates the calcium/calmodulin-dependent phosphatase 
calcineurin, leading to NFAT dephosphorylation and translocation into the nucleus. 
NFAT activity has been correlated with the induction of IL-2 expression in activated T 
cells [79]. Since anergic cells displayed a defective calcium response, I investigated 
whether there was a corresponding defect in NFAT regulation that corresponds to the 
reduced expression of IL-2 in anergic T cells. The translocation of the cytosolically 
distributed NFAT into the nucleus precedes transcriptional regulation. The role of 
NFAT1 has been extensively studied in T cell activation and altered regulation has been 
reported in some models of CD4+ T cell anergy [150]. Therefore I looked at the cellular 
distribution patterns of NFAT1 in anergic T cells after stimulation.  After stimulating T 
cells for different time points, the localization of NFAT1 in anergic cells was analyzed by 
immunofluorescence microscopy. In non-anergic cells, NFAT1 was seen as a cytosolic 
ring at two minutes after stimulation, and translocation into the nucleus was detected 
within five minutes of stimulation (Figure 4.2 A). By 30 minutes, NFAT1 had largely 
returned to the cytosol. In anergic T cells, NFAT1 was also detected in the cytosol after 2 
minutes of stimulation, but translocation into the nucleus was strongly reduced compared 
to naïve cells (Figure 4.2B). The level of NFAT1 nuclear localization was quantified and 
is represented in Figure 4.2 C. This indicates that the NFAT1 nuclear translocation is 
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Figure 4.2: NFAT1 translocation into the nucleus is impaired in anergic T cells. A. 
Naïve (responsive) T cells were stimulated for 2, 5 and 10 minutes with anti-CD3 and 
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anti-CD28 and secondary crosslinking anti-hamster IgG antibodies, or left unstimulated. 
Cells were incubated with anti-NFAT1 antibody followed by Alexa Fluor 594 anti-mouse 
IgG antibody. Nuclei were stained with SYTO13 (green, panels A-D), and NFAT1 
nuclear localization (red, panels E-H) was measured by immunofluorescence microscopy.  
Colocalization is shown in yellow in the merge images (yellow, panels I-L).  B. Anergic 
T cells were stimulated similar to naïve T cells, and NFAT1 nuclear translocation was 
measured as in A. C. Quantification of NFAT1 nuclear localization. Shown are combined 
averages (±s.d.) from three independent experiments. Colocalization was quantified from 
25 cells per individual experiment. *, p<0.05. ***, p<0.001 D. Western blot of NFAT1 in 
whole-cell lysates from resting (lane 1) and 5-minute stimulated (lane 2) naïve T cells. 
5x106 cells per sample were stimulated similar to immunofluorescence assays, and 














Surprisingly, we were unable to detect NFAT1 in resting naïve or anergic T cells, 
although the same antibody was able to detect NFAT1 in lysates from both resting and 
stimulated naïve T cells by Western blots (Figure 4.2 D). This suggests that the epitope 
(which is distinct from the nuclear localization signal) might be hidden prior to 
stimulation, either by protein conformation or by a binding partner. Stimulation 
presumably induces a conformational change in the protein that precedes nuclear 
translocation by minutes, allowing its detection in the cytosol. Interestingly, 2 minutes 
after stimulation, cytosolic distribution of NFAT1 was similar in anergic and naïve T 
cells. This suggests that NFAT1 in anergic cells also starts to undergo conformational 
changes due to dephosphorylation of the serine residues of the regulatory domain. The 
impaired ability of NFAT1 in anergic cells might be due to the incomplete 
dephosphorylation of enough serine residues to result in movement into the nucleus.  
 
A second explanation for the impaired nuclear NFAT localization in anergic cells could 
be that anergic cells might import NFAT1 into the nucleus at a rate equivalent to naïve T 
cells, but the simultaneous nuclear export of the protein is accelerated.  To address this 
possibility, tolerized T cells were stimulated in the presence or absence of leptomycin B, 
a nuclear export inhibitor [151].  As shown in Figure 4.3, leptomycin-treated anergic T 
cells displayed increased NFAT1 nuclear localization after stimulation, compared to 
leptomycin-untreated cells.  Although this result indicated that some NFAT1 was getting 
into the nuclei of anergic T cells, only to be quickly exported, the amount of nuclear 
localization in leptomycin-treated anergic cells after 30 minutes of stimulation was still 













































































































Figure 4.3: Leptomycin treatment of anergic T cells moderately enhances NFAT1 
nuclear accumulation. A. B., Anergic T cells were treated with 200µM Leptomycin B 
pre stimulation (panels D-F), or left untreated (panels A-C). Cells were stimulated as 
described above, for 5 minutes, 15 minutes and 30 minutes. T cells from control mice 
were also stimulated as described for 5 minutes (panel G). The nuclei were stained with 
SYTO 13. NFAT1 nuclear localization was determined by immunofluorescence and 
represented as colocalization of NFAT1 and SYTO 13 (merge, yellow). Colocalization 


















that a lowered rate of import is the major component of the reduced nuclear localization 
of NFAT1 in anergic cells.   
 
4.2.2 NFAT2 is regulated differently from NFAT 1 in anergic cells 
 
NFAT2 is another member of the NFAT family of proteins that is expressed in peripheral 
T lymphocytes. Previous studies using in vitro gel shift assays have shown that NFAT2 
binds the IL-2 promoter similar to NFAT1, and is also capable of interacting with AP-1 
to form productive transcriptionally active complexes [152]. Both isoforms appear able to 
activate transcription of many of the same genes [64]. However, most previous studies on 
NFAT localization have focused only on NFAT1. We therefore investigated if NFAT2 
displayed a similar pattern of nuclear translocation. In resting naive cells, we readily 
detected cytosolic NFAT2 (Figure 4.4A). However, unlike NFAT1, there was little 
translocation to the nucleus after stimulation, even after 30 minutes. Resting anergic T 
cells also showed cytosolic NFAT2, but displayed NFAT2 localization into the nucleus 
within five minutes of stimulation (Figure 4.4 B), when NFAT1 in these cells was largely 
cytosolic. We could detect nuclear localization of NFAT2 for at least 30 minutes after 
stimulation. NFAT2 nuclear colocalization was quantified and represented in Figure 4.4 
C. Thus, NFAT1 and NFAT2 are reciprocally regulated in naïve and anergic T cells. In 
naïve T cells, NFAT1, but not NFAT2, responds to TCR ligation by rapidly translocating 
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Figure 4.4: NFAT2 nuclear translocation is enhanced in anergic T cells. A, Naïve 
(responsive)  T cells were stimulated as in Figure 4.2 for 2, 5 and 30 minutes, and 
NFAT2 nuclear localization was determined by IF microscopy. Nuclei (green) are shown 
in the panels A-D, NFAT2 (red) in the panels E-H and colocalization (yellow) is shown 
in the panels I-L. B, Anergic T cells were stimulated as described and NFAT2 
localization was measured as in A. Nuclear colocalization is represented as the merge 
images (panels I-L). C, Quantification of NFAT2 nuclear localization using ImageJ. 25 
cells from each individual experiment were quantified.  Shown are combined averages (± 




4.2.3 NFAT1/2 translocation is controlled by extracellular calcium availability 
 
The correlation between the defective calcium signaling and the switch to NFAT2 
nuclear translocation in anergic cells suggested a causal connection. However, 
considering the complex network of signaling events that occur during T cell activation, 
anergic cells might be defective in other signaling modules. To determine if reduced 
calcium flux could account for the pattern of NFAT localization in anergic cells, I 
examined the translocation patterns of NFAT1 and NFAT2 in naïve T cells under 
conditions of calcium limitation.  
 
The calcium available to T cells was varied by using EGTA to chelate extracellular 
calcium. By titrating EGTA and measuring calcium flux by flow cytometry, I determined 
that the addition of 600-700 M EGTA to the T cell medium  produced calcium response 
curves similar to those seen in anergic T cells (Figure 4.5 A). Cells stimulated in medium 
with no added EGTA displayed NFAT1 nuclear localization (Figure 4.5 B, D, E) while 
NFAT2 remained cytosolic (Figure 4.5 C, D, E), as previously observed.  When 600 M 
EGTA was added to the medium, this pattern was reversed, with NFAT1 cytosolic and 
NFAT2 in the nucleus (Figure 4.5). In excess EGTA there was no NFAT nuclear 
localization, confirming that both NFAT1 and NFAT2 are dependent on the influx of 
extracellular calcium for activation. Thus, decreasing calcium signaling in T cells is 






















































































































































































































































































































Figure 4.5: Responsive T cells display the anergic NFAT1/2 translocation pattern 
when extracellular calcium availability is limited by the calcium chelator EGTA.  A. 
Measurement of calcium flux in naive T cells stimulated in the presence of 600µM 
EGTA. Naïve T cells were loaded with Fluo3 and Fura red, and calcium flux was 
measured as the ratio of Fluo3/Fura red fluorescence levels by flow cytometry. Basal 
fluorescence levels were measured for ~60 seconds, followed by stimulation of the cells 
with anti-CD3 and crosslinking anti-hamster IgG antibodies in the presence of 600µM 
EGTA. NFAT1 (B), and NFAT2 (C) localization was visualized using IF microscopy in 
resting cells (panels A,D,G), and in cells stimulated for 5 minutes in the absence (panels 
B,E,H) or in the presence of 600 M EGTA (C,F,I). Cells were stimulated as described 
above, and nuclear localization of NFAT1 and NFAT2 is represented as merge images 
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(yellow, panels G-I). D. Quantification of NFAT1 and NFAT2 nuclear localization in 
unstimulated cells (rest), and cells stimulated in the absence or presence of 600µM 
EGTA. Displayed are combined averages (±s.d.) from three independent experiments. 25 
cells per sample were quantified for each individual experiment. Statistical significance 
was determined between colocalization in the presence of 600µM EGTA versus 
colocalization in the absence of EGTA, or between colocalization in unstimulated cells 
versus colocalization in cells stimulated in the absence of EGTA. NFAT1 colocalization 
between various samples, and NFAT2 colocalization analysis between samples were 
done independently.   ***, p<0.001 E. Quantification of NFAT1 and NFAT2 nuclear 
localization in cells treated with 100µM, 300µM, 500µM, 600µM, 700µM, 800µM, 
900µM, 1mM and 5 mM EGTA and stimulated for 5 minutes. Graphs were generated 
with data from colocalization merge images from 25 cells per sample using ImageJ from 
one experiment. Statistical significance was determined between colocalization in the 
presence of various concentrations of EGTA versus colocalization in the absence of 
EGTA, and colocalization in unstimulated cells versus colocalization in cells stimulated 
in the absence of EGTA. Comparisons were done between independently for NFAT1 









In order to confirm that the effects of restricting calcium were not an artifact of using 
EGTA, the NFAT1 and NFAT2 translocation patterns were also determined by titrating 
BAPTA, another calcium chelator, into the medium. The calcium response curves 
obtained from titrating a range of concentrations of BAPTA corresponded to distribution 
obtained with EGTA, with increasing higher concentrations of BAPTA attenuating the 
peak influx of calcium after TCR stimulation. NFAT1 and NFAT2 showed normal 
distribution in naïve stimulated cells at lower range of BAPTA concentrations used. 
NFAT1 was preferentially localized in the nucleus while NFAT2 remained cytosolic. At 
300µM BAPTA, NFAT2 was detected in the nucleus, while NFAT1 localization was 
predominantly cytosolic, while both NFAT1 and 2 remained cytosolic in cells treated 
with higher concentrations of BAPTA (Figure 4.6). There was a higher degree of 
variability concerning the BAPTA concentrations that induced the pattern shift, 
compared to the consistent shift seen when cells were treated with 600µM EGTA.  
However, the nuclear localization patterns of NFAT2 were always similar to the pattern 
shift that was seen with EGTA treatment, although the concentrations of the chelator used 
were shifted.  
 
As a more direct approach I also looked at NFAT1 and 2 cellular distributions in naïve T 
cells resuspended in medium with defined calcium concentrations. Pharmacological 
compounds such as EGTA and BAPTA might perturb the cells in ways unrelated to the 
























































Figure 4.6: Differential NFAT1/2 translocation patterns are seen in responsive T 
cells stimulated in the presence of the calcium chelator BAPTA.  A. NFAT1 and 
NFAT2 nuclear translocation patterns were determined in naïve (responsive) T cells 
stimulated with anti-CD3/anti-CD28 and crosslinking anti-hamster IgG antibodies for 5 
minutes in the presence of 0, 100µM, 300µM, 400µM, 500µM and 800µM BAPTA by  IF 
microscopy. Cells were incubated with anti-NFAT1/2 antibody followed by Alexa Fluor 
594 anti-mouse IgG antibody (red). Nuclei were stained with SYTO13 (green).  Shown 
are the merge images for NFAT1/2 and the nuclei, which depict colocalization (yellow). 

















these unwarranted effects. At calcium concentrations corresponding to the amount of 
calcium present in RPMI-1640 (500µM), NFAT1 and NFAT2 cellular distributions were 
similar to cells in complete medium. However, there was little if no consistency in the 
correlation between calcium concentrations and the translocation patterns during different 
experimental trials. It is possible that directly reducing calcium in the medium might have 
resulted in differences in the ionic strength that could affect calcium signaling and NFAT 
nuclear trafficking or had other effects on the cells. 
 
4.2.4 NFAT2 localization in T cells is controlled at the level of nuclear import 
The results described above led me to hypothesize that the altered pattern of NFAT1 and 
NFAT2 localization in anergic, and calcium-limited cells might be due to differential 
sensitivities of the two proteins to calcineurin. To confirm this hypothesis, we treated 
cells with cyclosporin A to probe the effects of partial inhibition of calcineurin on nuclear 
localization of the two isoforms. Cyclosporin treatment also allowed us to specifically 
target the activity of calcineurin. Thus, any other molecular modifications ensuing from 
limiting calcium to the cells were avoided.  Naïve T cells were stimulated in the presence 
of titrated concentrations of cyclosporin A, and the cellular localization patterns were 
determined by immunofluorescence. As shown in Figure 4.7, partial inhibition of 
calcineurin with 300 nM  cyclosporin A blocked NFAT1 translocation but induced 
NFAT2 translocation, similar to the effects of 600 M EGTA.  Complete inhibition of 
calcineurin with 750 nM cyclosporin A caused cytosolic retention of both isoforms. Thus, 
a partial reduction in calcium signaling, by reducing either calcium influx or calcineurin 
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Figure 4.7: NFAT1 and NFAT2 reciprocal nuclear translocation is regulated by 
calcineurin activity. Purified naïve T cells were left untreated or treated with 150nM, 
300nM and 750nM of cyclosporin A and stimulated for 5 minutes as described above. 
The nuclei were stained withSYTO 13 (green). NFAT1 (A) and NFAT2 (B) nuclear 
localization (panels I, J, K and L) was visualized by immunofluorescence using Alexa 
Fluor 594 anti-mouse IgG antibodies to detect anti-NFAT1 or anti-NFAT2 (red), and 
quantified using Image J, as in Figure 4.3 (C,D). C. Displayed are combined averages 
(±s.d.) Statistical significance was determined between colocalization in the presence of 
EGTA and other concentrations of EGTA or unstimulated cells for both NFAT1 and 
NFAT2.25 cells per sample were quantified in each individual experiment. Statistical 
significance was determined between colocalization in the presence of various 
concentrations of CSA versus colocalization in the absence of CSA, or colocalization in 
unstimulated cells versus colocalization in cells stimulated in the absence of CSA. 
Significance values were generated for comparisons between colocalization of NFAT1 in 
the various samples. NFAT2 colocalization analysis was done independently, using the 
same comparisons. ***, p<0.001. **, p<0.01. D. Quantification of unstimulated cells 
(resting) and cells stimulated in the presence of 0 CSA, 150nM CSA, 250 nM CSA, 
300nM CSA and 750nM CSA. Shown are averages (±s.d.) from 25 cells per sample from 
one experiment. Statistical significance was determined between colocalization in the 
presence of various concentrations of CSA versus colocalization in the absence of CSA, 
or colocalization in unstimulated cells versus colocalization in cells stimulated in the 
absence of CSA. Significance values were generated for comparisons between 
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colocalization of NFAT1 in the various samples. NFAT2 colocalization analysis was 
























The nuclear localization of NFAT1/2 is determined by a balance in the rates of 
dephosphorylation by calcineurin and rephosphorylation of the same serine residues by 
NFAT kinases, which promote nuclear export. Some of these kinases, such as GSK3 
[153] and CK1 [139], act on both isoforms. Other kinases show specificity for one 
isoform, with p38 MAPK acting on NFAT1 [144] and JNK acting on NFAT2 [146]. To 
discern the effect of these proteins on the nuclear residence of NFAT1 and NFAT2, I 
stimulated T cells in the presence of pharmacological inhibitors of p38 and JNK and 
determined translocation patterns. The p38 inhibitor SB203580 had no effect on NFAT2 
(Figure 4.8). This is consistent with a role for p38 being a NFAT1 specific kinase. 
However, inhibition of JNK did not lead to increased nuclear NFAT2 out to 10 minutes 
of stimulation (Figure 4.9 A-C). The working concentration of the p38 inhibitor 
SB203580 was obtained from previously published studies while the concentrations used 
for the JNK inhibitor SP600125 was obtained by measuring inhibition of phosphorylation 
of c-Jun, a substrate of JNK activity (Figure 4.9 D).  From these results, it was inferred 
that regulation of NFAT2 in naïve T cells is upstream of nuclear entry.   
 
To confirm that the cytosolic localization of NFAT2 in stimulated naïve T cells was not 
actually due to rapid export, I stimulated T cells in the presence of the nuclear export 
inhibitor leptomycin B, and examined the pattern of NFAT1 and NFAT2 localization. As 
shown in Figure 4.10, treatment with 200nM leptomycin retained NFAT1 in the nucleus 
out to 30 minutes after stimulation. However, NFAT2 remained cytosolic even in the  
presence of leptomycin. The enhanced nuclear localization of NFAT1 in cells stimulated 
for 30 minutes, confirmes that  leptomycin B functions as a nuclear export inhibitor. 
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Figure 4.8: p38 inhibition does not affect NFAT2 cellular localization in responsive 
T cells. NFAT1 and NFAT2 nuclear translocation patterns were determined for naïve T 
cells treated with the p38 inhibitor SP230580. T cells were stimulated with anti-
CD3/anti-CD28 and secondary crosslinking anti-Hamster IgG antibodies for 5 and 10 
minutes in the presence or absence of 20µM SB230580 or left unstimulated. NFAT1 (A) 
and 2 (B) nuclear translocation patterns were determined by immunofluorescence, and 
represented as colocalization (yellow, panels K-O) between NFAT1/2 (red) and Syto 13 
(green). C. Colocalization was quantified using ImageJ with data from 25 cells per 
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Figure 4.9: Inhibiting Jnk activity does not affect translocation patterns of NFAT2 
in responsive T cells.  NFAT1 and NFAT2 cellular localization was determined in naïve 
T cells, stimulated in the presence of the JNK inhibitor SP600125. T cells were 
stimulated as described for 5 and 10 minutes in the presence or absence of 200µM 
SP600125 or left unstimulated. NFAT1 (A) and 2 (B) nuclear translocation patterns were 
determined by immunofluorescence and represented as colocalization (yellow, panels K-
O) between NFAT1/2 (red) and SYTO 13 (green). C. Colocalization was quantified using 
ImageJ with data from 25 cells per sample for each individual experiment. Shown are 
averages (±s.d.) from two independent experiments. D. Inhibition of JNK activity by 
SP600125 was determined by phosphorylation of c-Jun. Naïve T cells were stimulated 
for 5 and 10 minutes, in the presence or absence of 200µM SP600125, and phospho c-Jun 
values were determined by intracellular staining with PE- tagged antibodies by flow 
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Figure 4.10: NFAT2 localization is controlled at the level of nuclear import. NFAT1 
(A) and NFAT2 (B) nuclear translocation in the presence of the nuclear export inhibitor 
Leptomycin B was determined by immunofluorescence. Responsive T cells were 
stimulated for 5minutes and 30 minutes in the presence of 200µM Leptomycin B or left 
untreated. Cells were stimulated as described above, and nuclear localization was 
determined as the colocalization between NFAT1/2 (red) and the nuclei, stained with 
Syto 13 (green), represented in panels M-R.  C. Colocalization was quantified using 
ImageJ with data from 25 cells per sample from one experiment. Shown are averages 
(±s.d.). ***, p<0.001 
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Thus, the cellular localization NFAT2 is controlled at the level of nuclear import. 
Together, these results indicate that the altered regulation of NFAT translocation in 
anergic T cells is due to the reduced calcium flux and resultant reduction in calcineurin 
activity. 
4.2.5 Conditions that promote NFAT2 nuclear localization in naïve T cells 
inhibit T cell proliferation.  
NFAT1 and NFAT2 have been shown to bind the IL-2 promoter ARRE2 site in vitro 
[154]. In vivo, a cooperative interaction with AP-1 at the IL-2 promoter sites results in 
transcriptional activation. This suggests that under normal conditions of activation, when 
AP-1 formation is not affected, NFAT1 or NFAT2 nuclear residence and subsequent 
activation should result in IL-2 production and proliferation. To determine the 
proliferative ability of naïve T cells under conditions of NFAT2 nuclear entry, whole 
spleen cells were stimulated for 72 hours using titrated concentrations of anti-CD3 
antibody in the presence of 600µM EGTA or 300nM CSA. Whole spleen cells were used 
to provide the antigen presenting cells that provide costimulatory signals. The T cells  
treated with EGTA or CSA, displayed minimal to negligible proliferation and cell 
expansion (Figure 4.11 A). IL-2 production was also minimal in the cells that were 
stimulated in the presence of 600µM EGTA or 300nM CSA (Figure 4.11 B).  To 
ascertain that AP-1 formation is not affected by EGTA or CSA treatment, I looked at the 
phosphorylation of c-Jun and total c-fos levels in naïve T cells that were stimulated under 
conditions that promote NFAT2 nuclear entry. Phosphorylation of c-Jun was comparable 
in T cells treated with EGTA or CSA and cells left untreated up to 30 minutes after 
stimulation. Similarly, there were no differences in total c-fos levels during early 
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activation of T cells between EGTA or CSA treated cells, and untreated cells (Figure 
4.12). This suggests that the differences in IL-2 cytokine production and proliferative 
ability are not due to defective assembly of the AP-1 protein. T cells treated with EGTA 
and CSA differ from their untreated counterparts only in the NFAT2 versus NFAT1 
nuclear localization, upon stimulation. The inability to produce IL-2 is therefore an 
inherent characteristic of the NFAT2 that is found in the nucleus in these cells. Thus, 
though NFAT2 has been shown to bind the IL-2 promoter in vitro, it does not initiate IL-
2 transcription in naïve T cells. This suggests that NFAT2 has distinct function from 
NFAT1, at least in the transcriptional activation of IL-2. Stimulation of naïve T cells 
under conditions that promote NFAT2 nuclear localization, results in an unresponsive 



























































































Figure 4.11: T cell proliferation and IL-2 production is inhibited in conditions that 
promote NFAT2 nuclear localization. A. Proliferation measurements for naïve T cells 
stimulated with anti-CD3 antibodies and splenic APCs in the presence of 600µM EGTA 
or 300nM CSA. Splenic cells were stimulated in the presence of graded concentrations of 
anti-CD3 antibodies and EGTA/CSA for 72 hours at 37°C. [3H] Thymidine was added to 
the cells during the last 8 hours of stimulation. Proliferation was assayed by [3H] 
thymidine uptake in the cells. Shown is a representative of three indepdendent 
experiments. Statistical significance was determined between proliferation using 
complete RPMI and both treatments. ***, p<0.001 B. IL-2 production in naïve T cells 
was determined by ELISA. 1x106 purified T cells were stimulated in the presence of 
EGTA or CSA, with anti-CD3/anti-CD28 coated beads for 24 and 34 hours, and the 



















































Figure 4.12: AP-1 components are unaltered by conditions that promote NFAT2 
nuclear localization. Phospho c-Jun levels and c-fos levels were assayed by western blot 
analysis. Responsive T cells were stimulated in the presence of 600µM EGTA or 300nM 
CSA with anti-CD3/anti-CD28 coated beads for 5, 10, 15 and 30 minutes, or left 
unstimulated. Control cells were stimulated in the absence of EGTA or CSA. Cells were 
then lysed with RIPA buffer and assayed by western blot for (A) phospho c-Jun using 
antibodies specific for phosphorylation at Ser63 and (B) c-fos. Total c-Jun and actin 
levels were also assayed for as loading controls for A and B respectively. Shown are 








Intracellular mobilization of calcium is an important target of modulation in anergic T 
cells. NFAT regulation is one of the important downstream effects of calcium signaling 
in T cells. I therefore focused on the NFAT transcription factor family members NFAT1 
and NFAT2 and their cellular distribution, as these isoforms are expressed in peripheral T 
cells  and nuclear translocation of these isoforms requires the activation of the 
calcium/calmodulin-dependent phosphatase calcineurin [69, 131]. 
 
NFAT1 distribution was nuclear within five minutes of stimulation in naïve T cells, but 
NFAT1 failed to translocate in anergic T cells. The failure of NFAT1 to accumulate in 
the nuclei of anergic T cells could be explained by a decrease in nuclear import (due to 
reduced calcineurin activity) or an increase in nuclear export (via activation of nuclear 
NFAT kinases). The pattern of NFAT1 localization in anergic T cells treated with the 
nuclear export inhibitor leptomycin was examined, to distinguish between these options.  
Treated cells showed an increase in nuclear NFAT1, but required prolonged TCR ligation 
to approach the level seen in stimulated naive T cells.  Thus, although there may be some 
increase in NFAT kinase activity in anergic cells, this is unlikely to account fully for the 
blockade in nuclear NFAT1 accumulation.  I hypothesize that, in concert with any 
increased NFAT kinase activity, the reduced calcium flux lowers calcineurin activity 
enough to shift the balance from import to export. 
  
Interestingly, NFAT1 was undetectable in resting cells, but was detected in the cytosol 
after two minutes of stimulation in both naïve and anergic T cells. As I could detect 
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NFAT1 in Western blots of lysates from resting cells, this result suggests that nuclear 
localization of NFAT1 occurs in at least two distinct steps. First, TCR ligation causes a 
conformational shift in NFAT1, or induces release of a binding partner, which reveals the 
antibody epitope. This event appears to be independent of calcium flux, or has a 
relatively low threshold, as it occurs in both naïve and anergic T cells. The second step is 
the dephosphorylation and translocation of NFAT1, which is sensitive to calcium flux 
and is impaired in anergic cells. Although we hypothesize that these two steps are 
independently regulated by multiple pathways, they might both be mediated by 
calcineurin.  Calcineurin dephosphorylates up to 20 serine residues on the serine rich 
region (SRR) and the serine proline xx-repeat motif (SP)1 domains of NFAT1 in a 
specific order [73]. Dephosphorylation of the first residues may have a lower calcium 
requirement, whereas the final steps in uncovering the nuclear localization signal (NLS) 
require higher calcium concentrations. Further characterization of this process may reveal 
novel drug targets for the regulation of T cell activation. 
 
I also determined the cellular distribution of NFAT2 in anergic T cells. Although NFAT1 
and NFAT2 show a high degree of  homology in their DNA-binding Rel similarity 
domain (>70%) [62, 131], their translocation patterns after stimulation differed in naïve 
and anergic T cells. To my knowledge, this observation had not previously been reported. 
Unlike NFAT1, there was no nuclear translocation of NFAT2 for at least 30 minutes after 
stimulation of naïve T cells. Further, stimulation of anergic cells did lead to nuclear 
localization of NFAT2 within five minutes. Thus NFAT1 and NFAT2 seem to be 




By limiting calcium in the culture medium, I was also able to demonstrate that the 
reduction in calcium influx in anergic T cells is sufficient to account for the switch from 
NFAT1 to NFAT2 as the predominant translocating NFAT family member. Analysis of 
the nuclear translocation pattern of NFAT1 and 2 using the pharmacological inhibitors 
cyclosporin (inhibits calcineurin) and leptomycin (inhibits nuclear export) led to the 
conclusion that the reciprocal regulation takes place at the level of dephosphorylation 
prior to nuclear import. The involvement of nuclear NFAT kinases, which 
rephosphorylate the serine residues targeted by calcineurin, in controlling NFAT2 
localization in T cells seems to be limited, as stimulating naïve T cells in the presence of 
a JNK inhibitor during stimulation did not retain NFAT2 in the nucleus. Together, these 
results support a model in which localization of NFAT2 is controlled mainly by calcium-
dependent calcineurin activity, rather than rephosphorylation and nuclear export by JNK 
and other NFAT kinases. 
 
The reciprocal regulation of cellular distribution of NFAT1 and NFAT2 is not just a 
unique characteristic of CD8+ anergic T cells, but can be initiated in a mixed population 
of naïve T cells by modulating calcineurin activity. This phenomenon of differential 
regulation has also been reported in other cell types. Developing skeletal muscles have 
been reported to show NFAT2 nuclear localization in conjunction with cytosolic NFAT1 
[155]. The differences have been attributed to the activity of NFAT kinases that mediate 
export. This is the first instance where differential regulation upstream of nuclear entry 
has been reported. Increased knowledge about the various proteins that interact with 
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NFAT1 and NFAT2 in the cytosol and function as scaffolding proteins will aid in 
understanding the mechanism of NFAT1/2-specific regulation. Park et al, have identified 
a second calcineurin binding site for NFAT2 and NFAT4, toward the C terminal end of 
the regulatory domain [70]. This region is variable from the conserved PxIxIT 
arrangement and has been found to be necessary for calcineurin interaction with NFAT2 
and 4 in vivo. Interestingly, the peptide stretch corresponding to the second calcineurin 
binding region in NFAT1 did not mediate calcineurin binding in vitro. Calcineurin 
binding to this second site is therefore NFAT2-specific and could have important 
implications in NFAT1/2 dephosphorylation and cellular localization. For instance, the 
presence of two binding sites might decrease the concentration of calcineurin required to 
effect dephosphorylation and movement into the nucleus. Thus, the decreased calcium 
influx could stimulate sub-optimal calcinuerin activity enough for NFAT2 regulation, but 
lower than the threshold required for NFAT1 binding and subsequent dephosphorylation.  
 
Proteins that actively compete with calcineurin for NFAT binding have been identified 
for the PxIxIT binding site, common in all the members. The protein Homer, for instance, 
has been shown to bind the calcineurin binding site that is closest to the N terminus of the 
regulatory domain [147]. Mutational analysis has also shown that Homer does not bind to 
residues that have been implicated in the second calcineurin binding site of NFAT2 
[147]. The cytosolic organization of the NFAT-scaffolding protein complex might play 
an important role in the accessibility of calcineurin or the facilitation of translocating into 
the nucleus. Many molecules such as CABIN1 [77] and the DYRK kinases[143] have 
been identified to bind NFAT in the cytosol. A thorough analysis of the specific NFAT 
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proteins these molecules bind needs to be undertaken, to obtain a more comprehensive 
picture of NFAT cytosolic regulation upstream of nuclear entry. Differential regulation of 
NFAT1 and NFAT2 can be achieved by the individual activity or by concerted action of 
a number of NFAT interacting proteins, or by modulating upstream signaling events that 
feed into NFAT regulation.  
 
It is interesting to note that altering the NFAT1/NFAT2 nuclear entry patterns in naïve T 
cells is sufficient to inhibit proliferation and IL-2 production. This suggests that NFAT1 
and 2 have inherently different functions in the transcriptional activation of IL-2. It is 
tempting to speculate that NFAT2 might repress IL-2 transcription while NFAT1 might 
be the positive regulator of transcription, although detailed DNA binding and 
transcriptional analysis is required to confirm or disprove this hypothesis. Most studies 
regarding NFAT1 or 2 binding to the IL-2 promoter have been done using in vitro gel 
shift assays, which do not provide any information about positive or negative regulation 
of the gene involved. Analysis of expression patterns of genes such as TNFα [156, 157] 
and  IL-4 [158] in T cells, and IL-13 [159]  in mast cells have shown differences in  DNA 
binding patterns and transcriptional activity of NFAT1 and NFAT2. Thus NFAT1 and 
NFAT2, in spite of their similarities in DNA binding in vitro, might have a differential 
contribution to the physiological gene expression patterns of genes that have NFAT 
binding consensus sequences in their promoter/enhancer sites. 
 
This difference in NFAT utilization between responsive and anergic cells could be 
significant, in the establishment and maintenance of the anergic phenotype. One 
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hypothesis is that NFAT1 is responsible for the regulation of activation induced genes 
(e.g. IL-2), whereas NFAT2 is important for the expression of anergy related genes. 
Identification of NFAT2 controlled genes may therefore shed light on the factors 
responsible for maintaining the hyporesponsiveness of anergic T cells.  It is important to 
distinguish this from the events involved in establishing the anergic state, which occur 
during the initial exposure of T cells to antigen and are likely to involve NFAT1-
regulated genes [83].  
 
Despite the high degree of homology between NFAT1 and NFAT2, they have previously 
been shown to be non-redundant in T cells [69, 139, 144, 146]. Notably, NFAT1 and 
NFAT2 knockouts mice have different immunological phenotypes. NFAT1 deficient T 
cells are skewed toward a Th2 response, while NFAT2 knockout cells have a Th1 bias 
[65, 67, 68, 160]. Although it is not clear how this may relate to T cell anergy, 
particularly in CD8+ T cells, our observations suggest that regulation of calcium flux may 
also play a previously unsuspected role in T cell differentiation. Strong calcium signaling 
during stimulation may bias T cells toward a Th1 program by activating NFAT1, while 
sub optimal calcium signals would preferentially activate NFAT2, directing cells toward 
a Th2 bias. Investigation of the factors involved in the fine control of cellular calcium 












Anergy as a mechanism of tolerance has been extensively studied using various models 
of induction. T cells that have been stimulated in anergizing conditions, all primarily 
display hyporesposiveness and decreased clonal expansion, but there is no consensus on 
the molecular modulations that effect these functional changes. Presently, all these 
experimental in vitro and in vivo models of induction have been included in the definition 
of anergy, but may represent distinct sub optimally activated states of T cells. The 
comprehensive characterization of the signaling and transcriptional modifications 
corresponding to the different anergy models is necessary, for the further use of T cell 
anergy as a means of controlling T cell activation and function, primary goals in studies 
of autoimmunity, transplantation and tumor immunotherapy.  
 
The primary goal of my thesis is the characterization of the anergic phenotype of CD8+ T 
cells that interact with their cognate antigen in vivo, in a tolerogenic setting. Given the 
underlying biochemical differences and similarities in the various in vitro and in vivo 
models, I have attempted to characterize the important signaling manifestations that are 
exhibited during the secondary re-stimulation phase of anergy. Two major signaling 
pathways frequently found to be altered in anergic T cells are the ras/MAPK cascade and 
calcium signaling [92]. Although I could not detect consistent defects in MAPK 
activation in our model of in vivo anergy induction, I found that calcium responses in 
anergic cells were blunted relative to naïve cells. This is consistent with multiple other in 
vivo anergy models, spanning different induction methods and both CD4+ and CD8+ T 
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cells [96, 118, 126], suggesting that the calcium limitation is a common feature of in vivo 
T cell anergy.   
 
The decrease in the intracellular mobilization of calcium can be attributed to modulations 
in the proximal signaling events after TCR engagement. The activation of PLCγ that 
leads to the generation of IP3 appears to be the significant cause of lower calcium influx 
rates. Other systems have also reported alterations in the phosphorylation patterns of 
other molecules such as LAT and ZAP-70, along with a general decrease in the level of 
tyrosine phosphorylation. I have not examined these patterns, but reduced 
phosphorylation of PLCγ, which occurs downstream of phosphorylation of ZAP-70 and 
LAT, suggests that the 2C Tg anergic T cells might also display these defects. 
Nevertheless, these specific signaling events need to be characterized in our system of 
anergy, as the network of proximal signaling immediately after TCR engagement 
contributes to multiple downstream effects. A detailed analysis of events that precede 
PLCγ phosphorylation might aid in mapping out the key regulatory events that control 
the hyporesponsive phenotype. Mediating complete release of ER calcium in anergic T 
cells generates calcium responses similar to naïve T cells. This suggests that changes in 
the pre-ER signals dominate the calcium phenotype in anergic T cells. There are certain 
caveats to this interpretation, as discussed previously. However, the determination of 
downstream events mediated by calcium, such as NFAT cellular translocation in anergic 
T cells treated with thapsigargin or cell permeable IP3, will aid in determining if the 
calcium signaling defect in anergic T cells can be overcome by increasing the efficiency 




Another important consideration is the contribution of the second messengers cADPR 
and NAADP to calcium release from the intracellular stores. cADPR has been shown to 
bind the ryanodine receptors on the ER membrane [161], resulting the calcium release 
from the ER, in much the same way as  IP3-IP3R interactions [35]. Administration of 
NAADP into T cells has also been shown to result in calcium influx through the plasma 
membrane channels [41]. The signals downstream of TCR engagement,  that these 
second messengers recognize have not yet been characterized, but a potential role for 
these molecules in determining the calcium influx in anergic T cells cannot be 
overlooked. The effect of administration of cell permeable cADPR or NAADP on 
calcium signaling in anergic T cells would be informative in defining the role of these 
molecules in anergy regulation.  
 
The demonstration of defective calcium signaling not only helps in understanding the 
biochemical changes occurring in anergic T cells, but also provides a system to study the 
underlying mechanisms of calcium regulation in T cells. In an important study, human 
peripheral T cells isolated from some patients afflicted with severe combined immune 
deficiency showed pronounced calcium mobilization defects [56]. Further genetic 
analyses of these T cells and cells from the kin of the patients, contributed to the 
identification of Orai1, a protein that serves as the functional pore forming subunit of the 
plasma membrane CRAC channels [54], whose molecular identity had eluded scientists 
for many years [26]. The T cells isolated from these patients displayed impaired cytokine 
production and unresponsiveness to activating stimuli [55], but were distinct from anergic 
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T cells in that the defect in calcium signaling was post ER in the formation of the plasma 
membrane calcium channels, and therefore could not be restored by enabling complete 
ER release of calcium. Nevertheless, these studies demonstrate that the defective calcium 
signaling phenotype can be utilized as a model to identify key proteins that are involved 
in calcium regulation in T cells. 
 
The signaling alterations in anergic T cells cause an attenuation of intracellular calcium 
mobilization rather than a complete abrogation. This has been seen in my experiments 
with 2C TCR transgenic CD8+ T cells, as well as other CD4+ and CD8+ T cell anergy 
systems that have reported deviations in calcium signaling [118, 126]. The significance of 
this sub-optimal but detectable calcium influx has not been addressed before.  My 
observations on NFAT1 and NFAT2 cellular localization properties might therefore, be 
important in defining the functional relevance of anergic T cells. NFAT2 has been 
consistently detected in the nucleus of restimulated anergic T cells, and the nuclear 
localization of this protein is predominantly dependent on a low intensity of calcium 
influx. These results, therefore, suggest that the nuclear presence of NFAT2 in anergic T 
cells has transcriptional significance.  
 
Anergy is a reversible process. The proliferative ability of these cells can be restored by 
addition of IL-2 during restimulation [162-164]. Although the functional responsiveness 
of these anergy reversed T cells have been analyzed, the signaling mechanisms that 
underlie the restoration of T cell responsiveness has not been addressed. Studies on 
rapamycin induced anergy have  shown that anergy reversal is inhibited in the presence 
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of rapamycin, implicating mTOR as a possible signaling regulator in anergy reversal 
[100]. IL-2/IL-2 receptor signaling is mainly effected through the downstream Jak-STAT 
pathways, resulting in the upregulation of anti-apoptotic genes such as Bcl-2 [165], and 
in CD8+ T cells, genes that are important for cytolytic effector functions, such as perforin 
and granzyme [166]. Among the other important signaling pathways that are activated by 
IL-2 /IL-2 receptor binding are the MAPK pathway, leading to upregulation of c-Fos and 
the PI-3K pathway, which mediates proliferation through multiple mechanisms [167]. It 
is necessary, therefore, to study the specific signaling and transcriptional effects of IL-2 
on anergic T cells, to determine the signaling components important for anergy reversal.   
 
The role of calcium signaling and the downstream NFAT activation cascade, in restoring 
functional responsiveness has not been characterized yet. Possible interactions between 
IL-2 receptor mediated signaling and the calcium-NFAT cascade might explain the 
potential role for NFAT in anergy reversal. Since anergy is not a terminal differentiation 
process, the complete abolishment of critical signaling components by ubiquitination 
might be counter productive to the cells. By partially impairing the important signaling 
cascades that mediate full activation, resulting in NFAT2 nuclear localization, anergy, in 
T cells might be an intermediate state that might be reverted in the presence of 
proliferating signals such as IL-2. It is therefore important to determine the gene 
expression patterns of anergy reverted T cells, in comparison to activated or anergic cells, 
and to also determine if there is a repression in the transcription of the anergy related 
genes, such as the E3 ubiquitin ligases or DGKα. An intriguing possibility then would be 
that NFAT2 nuclear accumulation in anergic T cells is to facilitate a transcriptional 
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repression of these anergy genes, when synergized with IL-2/IL-2 receptor signaling 
effects. This hypothesis, therefore suggests the possibility of NFAT2 functioning as a 
transcriptional repressor, as opposed to being a positive regulator, of the anergy genes, as 
was hypothesized before. Thus, rather than maintaining the anergic phenotype, NFAT2 
might be the enabler of anergy reversal (Figure 5.1). Determination of cellular 
localization patterns of both NFAT1 and NFAT2 during anergy reversal might provide 
more information in proving or disproving this hypothesis. Also specific gene array 
analysis from anergic and anergy reverted cells might also provide information about the 
transcriptional regulation of the anergy related genes.  
 
Yet another mechanism of tolerance is active suppression. Studies have shown that the 
state of anergy can lead to the generation of regulatory T cells [168]. In fact in a number 
of CD4+ studies, the terminology of anergy is also used to describe regulatory T cells, 
due to the functional unresponsiveness also seen in the suppressor cells. Regulatory T 
cells are characterized by the upregulation in expression of the transcription factor Foxp3 
[169]. Foxp3 expression is controlled by NFAT-Smad3 cooperation [86]. This study was 
done looking at NFAT1-Smad3 interactions, so it is not known if NFAT2 also elicits 
Foxp3 transcription. Interestingly, NFAT/Foxp3/DNA interaction has also been reported 
[85, 132, 170, 171]. NFAT/Foxp3/DNA interactions that are formed are analogous to the 
NFAT/AP-1/DNA interactions, but act as functional repressors of IL-2, while promoting 
transcription of genes involved in the regulatory phenomenon, such as CD25 and CTLA-
4 [85].  It is therefore a pertinent question to ask if NFAT2 nuclear movement is a 
































Figure 5.1: Possible roles of NFAT2 during anergy maintanence and anergy  
 
reversal. Nuclear localization of NFAT1 under conditions of complete T cell activation 
results in the upregulation of genes such as IL-2 and IFNγ that dictate the productive 
immune response. NFAT2 is localized in the nucleus during anergy and might contribute 
to the activation of genes that are responsible for the unresponsive phenotype. NFAT2 
could also be involved in the regulation of genes during anergy reversal, in cooperation 
with signals generated downstream of the IL-2/ IL-2R signaling cascades. Thus NFAT2 
could potentially regulate gene expression of both negative or positive regulatory genes 









T cells.  CD8+ T cells have traditionally not been described as suppressor cells, but there 
is increasing evidence that a pool of CD8+ regulatory cells can exist [172]. 
 
My studies therefore have shown that anergy in CD8+ T cells results in the differential 
regulation of cellular accumulation of NFAT1 and NFAT2. This is a previously 
unreported finding that highlights the possible functional differences in proteins that 
share a high degree of sequence similarity and a broadly similar mechanism of activation 
in stimulated T cells. I have shown that the 2C TCR Tg CD8+ anergic cells display 
defective intracellular mobilization of calcium, and that this defect is the predominant 
causal feature of the differential NFAT mobilization that is seen. This differential 
regulation, which can be emulated in naïve T cells by regulating calcium availability or 
calcineurin activity, thus provides a novel means of controlling the activation of specific 
transcriptional factors and expression of the relevant genes involved, based on the 
strength of TCR stimulation.  
 
It is important to measure transcriptional activity of NFAT1 and NFAT2 before assigning 
physiological significance to the nuclear accumulation of NFAT2 in anergic T cells. I 
acknowledge that an important caveat to all the hypotheses presented above is that 
NFAT2 nuclear accumulation in anergic T cells might not have any transcriptional 
significance. Many more experiments need to be conducted to characterize the functional 
activity of nuclear NFAT2, both in anergic T cells and in cells that have been stimulated 
in conditions promoting NFAT2 nuclear entry, looking at expression patterns of genes 
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involved in both activation and anergy. The results from those studies will definitely 
enrich conclusions from my studies on differential regulation of NFAT in T cells. 
 
Over the past few years, NFAT has emerged as a master regulator of T cell 
differentiation, owing to the vast number of genes, whose expression is regulated by 
NFAT activity. NFAT, either alone, or in concert with various other binding partners is 
involved in regulating gene expression during Th1 differentiation, during Th2 
differentiation and during the establishment of the Th17 phenotype. Thus productive 
immune reponse under any antigenic context is dependent on NFAT activity. NFAT has 
also been implicated in anergy induction and the establishment of the T regulatory 
phenotype. Thus NFAT also controls of inhibition of T cell responses. The specificity of 
the isoform involved in these gene expression events has not been comprehensively 
identified. My results, which show that the strength of calcium signaling activates one or 
the other isoform of NFAT, reiterates the importance of studying the diferential usage of 
NFAT1 and NFAT2. Thus, along with the particular binding partner involved, the 
specificity of the NFAT isoform might be an important determinat in driving naïve T 
cells down distinct programs of differentiation. 
 
5.1 Future studies 
 
Future studies will focus on determining differential transcriptional activity of NFAT1 
and NFAT2 in anergic T cells, and also in anergic T cells that have been treated with IL-
2. Comprehensive gene array experiments comparing expression patterns of genes 
involved in activation, anergy, and anergy reversal will help in identifying the underlying 
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molecular mechanisms that regulate these phenotypes. Chromatin immunoprecipitation 
(ChIP) assays for NFAT1 and NFAT2 will aid in identifying specific genes as being 
regulated by NFAT1 or 2. CHIP-on-ChIP assays are based on gene array studies on DNA 
that is generated from chromatin-IP experiments, and can therefore be important tools to 
identify all the genes that are specifically regulated by each NFAT family member. Gene 
expression patterns generated from these experiments will provide conclusive evidence 
regarding the transcriptional role of NFAT2. These experiments will also aid in 
identifying new genes involved in calcium regulation, and establishing their expression 
patterns in anergic T cells.  
 
Knockout mice have been previously used to elucidate the roles NFAT1 and NFAT2 play 
in T cell development and anergy induction. Mutant mice cannot be used in the studies 
discussed above, due to the dual role of NFAT in anergy induction and anergy 
maintenance. Therefore siRNA knockdown of NFAT1 or NFAT2 can be used to 
determine the phenotype of T cells that undergo stimulation in activating or anergizing 
conditions, in the absence of NFAT1 or NFAT2. Analysis of expression of specific genes 
in these siRNA targeted cells is yet another way of determining the transcriptional 
activity of NFAT2. Anergic T cells are highly refractory to genetic manipulation, due to 
their quiescent state, and to circumvent this limitation, the Gajewski lab have generated 
CAR (coxsackie/adenovirus receptor) Tg mice, which allows for efficient transduction of 
resting, non proliferating cells. CAR Tg T cells can be transduced with recombinant 
adenovirus carrying the gene or construct of interest [173]. By genetically engineering 2C 
TCR Tg cells that also express this receptor, these technical difficulties can be 
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circumvented. Conducting these experiments in T cell clones derived from cell lines is 
another option for elucidating transcriptional activity specific for NFAT1 or NFAT2.  
 
The determination of NFAT1 and NFAT2 transcriptional activity by the above mentioned 
strategies will be important in establishing the individual role, these transcription factors 























































































































Appendix: Anergic CD8+ T cells display a calcium signaling defect.  Anergic and 
naïve T cells were loaded with Fluo3 and Fura Red, and intracellular calcium responses 
to anti-CD3 and secondary crosslinking antibody stimulation were determined by flow 
cytometry. The basal fluorescence levels of Fluo3 and Fura red in the cells were 
measured for the first 60 seconds, before addition of the stimulatory crosslinking anti-
hamster IgG antibody. A,B. Intracellular calcium responses to anti-CD3 stimulation were 
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